0001683168-17-002009.txt : 20170809 0001683168-17-002009.hdr.sgml : 20170809 20170809150503 ACCESSION NUMBER: 0001683168-17-002009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170809 DATE AS OF CHANGE: 20170809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RadNet, Inc. CENTRAL INDEX KEY: 0000790526 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133326724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33307 FILM NUMBER: 171017565 BUSINESS ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 3104787808 MAIL ADDRESS: STREET 1: 1510 COTNER AVE CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: PRIMEDEX HEALTH SYSTEMS INC DATE OF NAME CHANGE: 19930518 FORMER COMPANY: FORMER CONFORMED NAME: CCC FRANCHISING CORP DATE OF NAME CHANGE: 19920703 10-Q 1 radnet_10q-063017.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-33307

RadNet, Inc.

(Exact name of registrant as specified in charter)

Delaware	13-3326724
(State or other jurisdiction of Incorporation or organization)	(I.R.S. Employer Identification No.)


1510 Cotner Avenue
Los Angeles, California	90025
(Address of principal executive offices)	(Zip Code)

(310) 478-7808

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

	Large accelerated filer o	Accelerated filer x
	Non-accelerated filer o	Smaller reporting company o
	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No x

The number of shares of the registrant’s common stock outstanding on August 4, 2017 was 47,266,352 shares.

RADNET, INC.

Table of Contents

	Page

PART I – FINANCIAL INFORMATION	3

ITEM 1. Condensed Consolidated Financial Statements (unaudited)	3

Condensed Consolidated Balance Sheets at June 30, 2017 and December 31, 2016	3

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 and 2016	4

Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2017 and 2016	5

Condensed Consolidated Statement of Stockholders’ Equity for the Six Months Ended June 30, 2017 and 2016	6

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016	7

Notes to Condensed Consolidated Financial Statements	9

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	23

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	39

ITEM 4. Controls and Procedures	40

PART II – OTHER INFORMATION	42

ITEM 1. Legal Proceedings	42

ITEM 1A. Risk Factors	42

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	42

ITEM 3. Defaults Upon Senior Securities	42

ITEM 4. Mine Safety Disclosures	42

ITEM 5. Other Information	42

ITEM 6. Exhibits	42

SIGNATURES	43

INDEX TO EXHIBITS	44

PART I - FINANCIAL INFORMATION

Item 1 – Financial Statements

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

	June 30,			December 31,
	2017			2016
	(unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	12,707		$	20,638
Accounts receivable, net		170,155			164,210
Due from affiliates		3,087			2,428
Prepaid expenses and other current assets		21,702			28,435
Assets held for sale		–			2,203
Total current assets		207,651			217,914

PROPERTY AND EQUIPMENT, NET		253,179			247,725
OTHER ASSETS
Goodwill		244,464			239,553
Other intangible assets		41,506			42,682
Deferred financing costs		1,806			2,004
Investment in joint ventures		48,500			43,509
Deferred tax assets, net of current portion		48,416			50,356
Deposits and other		6,298			5,733
Total assets	$	851,820		$	849,476

LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable, accrued expenses and other	$	107,452		$	111,166
Due to affiliates		12,079			13,141
Deferred revenue		1,961			1,516
Current portion of deferred rent		2,991			2,961
Current portion of notes payable		21,933			22,031
Current portion of obligations under capital leases		5,384			4,526
Total current liabilities		151,800			155,341

LONG-TERM LIABILITIES
Deferred rent, net of current portion		26,429			24,799
Notes payable, net of current portion		598,020			609,445
Obligations under capital lease, net of current portion		3,632			2,730
Other non-current liabilities		8,290			5,108
Total liabilities		788,171			797,423

EQUITY
RadNet, Inc. stockholders' equity:
Common stock - $.0001 par value, 200,000,000 shares authorized; 47,266,352, and 46,574,904 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively		4			4
Additional paid-in-capital		204,417			198,387
Accumulated other comprehensive (loss) gain		(1,394	)		306
Accumulated deficit		(146,111	)		(150,211	)
Total RadNet, Inc.'s stockholders' equity		56,916			48,486
Noncontrolling interests		6,733			3,567
Total equity		63,649			52,053
Total liabilities and equity	$	851,820		$	849,476

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016
NET REVENUE
Service fee revenue, net of contractual allowances and discounts	$	214,056		$	203,759		$	426,806		$	404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue		230,014			218,565			459,027			434,953
OPERATING EXPENSES
Cost of operations, excluding depreciation and amortization		198,611			194,062			404,065			390,888
Depreciation and amortization		16,612			15,811			33,266			32,223
Loss on sale and disposal of equipment		453			441			408			441
Severance costs		177			173			380			340
Total operating expenses		215,853			210,487			438,119			423,892
INCOME FROM OPERATIONS		14,161			8,078			20,908			11,061

OTHER INCOME AND EXPENSES
Interest expense		10,303			10,745			20,543			21,426
Meaningful use incentive		–			–			(250	)		(2,808	)
Equity in earnings of joint ventures		(2,994	)		(3,274	)		(4,922	)		(5,553	)
Gain on sale of imaging centers		(2,301	)		–			(2,301	)		–
Gain from return of common stock		–			(5,032	)		–			(5,032	)
Other expenses		7			4			10			6
Total other expenses		5,015			2,443			13,080			8,039
INCOME BEFORE INCOME TAXES		9,146			5,635			7,828			3,022
Provision for income taxes		(3,523	)		(2,256	)		(3,065	)		(750	)
NET INCOME		5,623			3,379			4,763			2,272
Net income (loss) attributable to noncontrolling interests		313			(243	)		663			47
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$	5,310		$	3,622		$	4,100		$	2,225

BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$	0.11		$	0.08		$	0.09		$	0.05

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$	0.11		$	0.08		$	0.09		$	0.05

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic		46,756,276			46,558,944			46,662,420			46,576,631
Diluted		47,195,898			46,882,383			47,068,563			46,960,226

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(IN THOUSANDS)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
NET INCOME	$	5,623		$	3,379		$	4,763		$	2,272
Foreign currency translation adjustments		20			(20	)		22			(16	)
Change in fair value of cash flow hedge, net of taxes		(944	)		–			(1,722	)		–
COMPREHENSIVE INCOME		4,699			3,359			3,063			2,256
Less comprehensive income (loss) attributable to noncontrolling interests		313			(243	)		663			246
COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$	4,386		$	3,602		$	2,400		$	2,010

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

The following table summarizes changes in the Company’s consolidated stockholder’s equity, including noncontrolling interest, during the six months ended June 30, 2017.

					Additional		Accumulated Other						Radnet, Inc.
	Common Stock				Paid-in		Comprehensive			Accumulated			Stockholders’			Noncontrolling			Total
	Shares		Amount		Capital		Gain (Loss)			Deficit			Equity			Interests			Equity
BALANCE - JANUARY 1, 2017		46,574,904	$	4	$	198,387	$	306		$	(150,211	)	$	48,486		$	3,567		$	52,053
Stock-based compensation		–		–		4,114		–			–			4,114			–			4,114
Issuance of restricted stock and other awards		691,448		–		99		–			–			99			–			99
Sale to noncontrolling interests, net of taxes		–		–		1,817		–			–			1,817			–			1,817
Contributions from noncontrolling interests		–		–		–		–			–			–			3,158			3,158
Distributions paid to noncontrolling interests		–		–		–		–			–			–			(655	)		(655	)
Change in cumulative foreign currency translation adjustment		–		–		–		22			–			22			–			22
Change in fair value cash flow hedge, net of taxes		–		–		–		(1,722	)		–			(1,722	)		–			(1,722	)
Net income		–		–		–		–			4,100			4,100			663			4,763
BALANCE - JUNE 30, 2017		47,266,352	$	4	$	204,417	$	(1,394	)	$	(146,111	)	$	56,916		$	6,733		$	63,649

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(unaudited)

	Six Months Ended June 30,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	4,763		$	2,272
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		33,266			32,223
Provision for bad debts		23,500			22,630
Gain from return of common stock		–			(5,032	)
Equity in earnings of joint ventures		(4,922	)		(5,553	)
Distributions from joint ventures		3,993			2,098
Amortization deferred financing costs and loan discount		1,636			2,738
Loss on sale and disposal of equipment		408			441
Gain on sale of imaging centers		(2,301	)		–
Stock-based compensation		4,314			3,761
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable		(29,445	)		(24,873	)
Other current assets		4,553			8,454
Other assets		(835	)		220
Deferred taxes		1,940			10
Deferred rent		1,830			1,052
Deferred revenue		445			–
Accounts payable, accrued expenses and other		7,014			10,983
Net cash provided by operating activities		50,159			51,424

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities		(9,904	)		(6,603	)
Investment at cost		(500	)		–
Purchase of property and equipment		(42,647	)		(40,267	)
Proceeds from sale of equipment		63			63
Proceeds from sale of imaging facilities		5,627			–
Cash distribution from new JV partner		1,473			994
Equity contributions in existing and purchase of interest in joint ventures		(80	)		(734	)
Net cash used in investing activities		(45,968	)		(46,547	)

CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable		(3,769	)		(6,310	)
Payments on Term Loan Debt		(12,125	)		(12,357	)
Deferred financing costs and debt discount		(570	)		–
Distributions paid to noncontrolling interests		(655	)		(157	)
Proceeds from sale of noncontrolling interest, net of taxes		4,850			–
Contributions from noncontrolling partners		125			–
Proceeds from revolving credit facility		139,400			235,500
Payments on revolving credit facility		(139,400	)		(221,700	)
Proceeds from issuance of common stock upon exercise of options		–			150
Net cash used in financing activities		(12,144	)		(4,874	)

EFFECT OF EXCHANGE RATE CHANGES ON CASH		22			(16	)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(7,931	)		(13	)
CASH AND CASH EQUIVALENTS, beginning of period		20,638			446
CASH AND CASH EQUIVALENTS, end of period	$	12,707		$	433

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest	$	19,023		$	18,545

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(unaudited)

Supplemental Schedule of Non-Cash Investing and Financing Activities

We acquired equipment and certain leasehold improvements for approximately $17.5 million and $15.4 million during the six months ended June 30, 2017 and 2016, respectively, which were not paid for as of June 30, 2017 and 2016, respectively. The offsetting amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.

During the six months ended June 30, 2017 and 2016 we added capital lease debt of approximately $5.2 million and $1.3 million, respectively.

During the six months ended June 30, 2017 we recorded an investment in joint venture of $3.0 million to ScriptSender LLC representing our capital contribution to the venture. The offsetting amount was recorded on the due to affiliates account of ScriptSender, LLC. See Note 4, Facility Acquisitions and Dispositions to the condensed consolidated financial statements contain herein for further information.

We transferred approximately $2.5 million in net assets in April 2017 to our new joint venture, Santa Monica Imaging Group LLC. See Note 4, Facility Acquisitions and Dispositions to the condensed consolidated financial statements contain herein for further information.

RADNET, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At June 30, 2017, we operated directly or indirectly through joint ventures with hospitals, 295 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.

The consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc. The consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

Accounting Standards Codification (“ASC”) 810-10-15-14, Consolidation, stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

Howard G. Berger, M.D., is our President and Chief Executive Officer, a member of our Board of Directors, and also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at nearly all of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups.

We contract with nine medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Six of these groups are owned by John V. Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors, and a 1% owner of BRMG. Dr Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities.

RadNet provides non-medical, technical and administrative services to BRMG and the nine medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. Through the management agreement with us, all cash flows of BRMG and the NY Groups are transferred to us.

We have determined that BRMG and the NY Groups are VIE’s, and that we are the primary beneficiary, and consequently, we consolidate the revenue and expenses, assets and liabilities of each. BRMG and the NY Groups on a combined basis recognized $33.5 million and $33.0 million of revenue, net of management service fees to RadNet, for the three months ended June 30, 2017 and 2016, respectively, and $33.5 million and $33.0 million of operating expenses for the three months ended June 30, 2017 and 2016, respectively. RadNet recognized in its condensed consolidated statement of operations $108.2 million and $104.1 million of net revenues for the three months ended June 30, 2017, and 2016 respectively, for management services provided to BRMG and the NY Groups relating primarily to the technical portion of total billed revenue.

BRMG and the NY Groups on a combined basis recognized $69.0 million and $66.9 million of revenue, net of management service fees to RadNet, for the six months ended June 30, 2017 and 2016, respectively, and $69.0 million and $66.9 million of operating expenses for the six months ended June 30, 2017 and 2016, respectively. RadNet recognized in its condensed consolidated statement of operations $221.5 million and $208.0 million of net revenues for the six months ended June 30, 2017, and 2016 respectively, for management services provided to BRMG and the NY Groups relating primarily to the technical portion of total billed revenue.

The cash flows of BRMG and the NY Groups are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at June 30, 2017 and December 31, 2016, we have included approximately $104.0 million and $100.0 million, respectively, of accounts receivable and approximately $11.2 million and $9.0 million of accounts payable and accrued liabilities related to BRMG and the NY Groups.

The creditors of BRMG and the NY Groups do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of BRMG and the NY Groups. However, both BRMG and the NY Groups are managed to recognize no net income or net loss and, therefore, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

At all of our centers we have entered into long-term contracts with radiology groups in the area to provide physician services at those facilities. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities, we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. Except in New York City, the fee is based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. In New York City we are paid a fixed fee set in advance for our services. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no financial controlling interest in the radiology practices. Because of the controlling relationship of Dr. Berger and Dr. Crues in the California and New York City practices as stated in detail above, we consolidate the revenue and expenses.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2017 and 2016 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2016, as amended.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended.

ADOPTION OF ASU 2016-09 – Compensation – Stock Compensation - In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09 (“ASU 2016-09”), Compensation—Stock Compensation, (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires excess tax benefits and tax deficiencies, which arise due to differences between the measure of compensation expense and the amount deductible for tax purposes, to be recorded directly through the statement of operations when awards vest or are settled. We elected to early adopt the new guidance for the year ended December 31, 2016. Upon adoption using the modified retrospective transition method, we recorded a cumulative effect adjustment to recognize previously unrecognized excess tax benefits which increased deferred tax assets and reduced accumulated deficit by $7.1 million. The current net tax benefit for 2016 resulting from adoption of the new guidance is approximately $400,000 and was reflected in our tax provision at December 31, 2016. The impact on our quarterly financial result for the three months ended June 30, 2016 was additional income tax expense of approximately $3,000. The impact on our financial statements for the six months ended June 30, 2016 is as follows:

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

In thousands except per share data	As previously reported			Impact of adoption		As currently reported
Provision for income taxes	$	(1,073	)	$	323	$	(750	)
Net income		1,949			323		2,272
Net income attributable to Radnet Inc. common shareholders		1,902			323		2,225
Basic and diluted income per share		0.04			0.01		0.05

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands	As previously reported			Impact of adoption			As currently reported
Net income	$	1,949		$	323		$	2,272
Deferred taxes		333			(323	)		10
Others		(2,295	)		–			(2,295	)
Net decrease in cash and cash equivalents	$	(13	)	$	–		$	(13	)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

In thousands	As previously reported			Impact of adoption		As currently reported
Net income	$	1,949		$	323	$	2,272
Foreign currency translation adjustments		(16	)		–		(16	)
Comprehensive income		1,933			323		2,256
Less comprehensive income attributable to non-controlling interests		47			–		47
Comprehensive income attributable to Radnet Inc. common shareholders	$	1,886		$	323	$	2,209

REVENUES -Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. As it relates to BRMG and the NY Groups centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Groups as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Groups. As it relates to non-BRMG and NY Groups centers, namely the affiliated physician groups, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Service fee revenues are recorded during the period the services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances are based on historical collection rates of payor reimbursement contract agreements. We also record a provision for doubtful accounts based primarily on historical collection rates related to patient copayments and deductible amounts for patients who have health care coverage under one of our third-party payors.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Commercial insurance	$	142,691		$	134,962		$	283,683		$	266,439
Medicare		47,611			45,558			95,291			91,385
Medicaid		6,525			6,890			13,259			13,915
Workers' compensation/personal injury		8,867			8,966			17,925			18,485
Other⁽¹⁾		8,362			7,383			16,648			14,377
Service fee revenue, net of contractual allowances and discounts		214,056			203,759			426,806			404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue	$	230,014		$	218,565		$	459,027		$	434,953

___________________

⁽¹⁾ Other consists of revenue from teleradiology services, consulting fees and software revenue.

PROVISION FOR BAD DEBTS - We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by the historical payment patterns of each type of payor, write-off trends, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

MEANINGFUL USE INCENTIVE - Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software can be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $250,000 and $2.8 million during the six months ended June 30, 2017 and 2016, respectively, relating to this incentive.

DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.8 million and $2.0 million, as of June 30, 2017 and December 31, 2016, respectively and related to the Company’s line of credit. In conjunction with our Fourth Amendment to our First Lien Credit Agreement (as defined below), a net addition of approximately $27,000 was added to deferred financing costs. See Note 5, Revolving Credit Facility, Notes Payable, and Capital Leases for more information.

INVENTORIES - Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 30 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATION - Accounting for acquisitions requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

GOODWILL- Goodwill at June 30, 2017 totaled $244.5 million. Goodwill is recorded as a result of business combinations. Management evaluates goodwill at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. We tested goodwill for impairment on October 1, 2016, noting no impairment, and have not identified any indicators of impairment through June 30, 2017. Activity in goodwill for the six months ended June 30, 2017 is provided below (in thousands):

Balance as of December 31, 2016		239,553
Goodwill acquired through the acquisition of Resolution Imaging Medical Corp		1,901
Goodwill acquired through the acquisition of MRI Centers of Torrance		401
Goodwill disposed through the transfer to Santa Monica Imaging Group JV		(1,901	)
Goodwill acquired through the acquisition of D&D Diagnostics, Inc.		1,519
Goodwill acquired through the acquisition of Stockton MRI, Inc.		3,101
Goodwill disposed through the sale of Hematology Oncology		(110	)
Balance as of June 30, 2017	$	244,464

INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.

EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. As of June 30, 2017, we have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 6 Stock-Based Compensation for more information.

COMPREHENSIVE INCOME - ASC 220, Comprehensive Income, establishes rules for reporting and displaying comprehensive income and its components. Our unrealized gains or losses on foreign currency translation adjustments are included in comprehensive income. For the quarter ended December 31, 2016, we entered into an interest rate cap agreement. Assuming perfect effectiveness, any unrealized gains or losses related to the cap agreement that qualify for cash flow hedge accounting are classified as a component of comprehensive income. Any ineffectiveness is recognized in earnings. The components of comprehensive income for the three and six months in the period ended June 30, 2017 are included in the condensed consolidated statements of comprehensive income.

DERIVATIVE INSTRUMENTS - In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued over the life of the 2016 Caps.

At inception, we designated our interest rate cap agreements as cash flow hedges of floating-rate borrowings. In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e., change in fair value) is initially reported as a component of accumulated other comprehensive income in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As of June 30, 2017, the cash flow hedges were deemed to be effective. No amount is expected to be reclassified into earnings in the next twelve months.

Below represents as of June 30, 2017 the fair value of our 2016 Caps and loss recognized:

The fair value of derivative instruments as of June 30, 2017 is as follows (amounts in thousands):

Derivatives	Balance Sheet Location	Fair Value – Liabilities
Interest rate contracts	Current and other non-current liabilities	$(1,970)

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss is as follows (amounts in thousands):

For the three months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($944)	Other Comprehensive Loss


For the six months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($1,722)	Other Comprehensive Loss

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our consolidated balance sheets, as follows (in thousands):

	As of June 30, 2017
	Level 1		Level 2			Level 3		Total
Current and other non-current liabilities
Interest Rate Contracts	$	–	$	(1,970	)	$	–	$	(1,970	)

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total
Current assets
Interest Rate Contracts	$	–	$	818	$	–	$	818

The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.

The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):

	As of June 30, 2017
	Level 1		Level 2		Level 3		Total Fair Value		Total Face Value
First Lien Term Loans	$	–	$	468,564	$	–	$	468,564	$	466,813
Second Lien Term Loans	$	–	$	169,260	$	–		169,260	$	168,000

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total		Total Face Value
First Lien Term Loans	$	–	$	483,129	$	–	$	483,129	$	478,938
Second Lien Term Loans	$	–	$	167,580	$	–	$	167,580	$	168,000

Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.

The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.

EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Net income attributable to RadNet, Inc.'s common stockholders	$	5,310	$	3,622	$	4,100	$	2,225

BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Basic net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Add nonvested restricted stock subject only to service vesting		250,153		77,162		198,477		155,447
Add additional shares issuable upon exercise of stock options and warrants		189,469		246,277		207,666		228,148
Weighted average number of common shares used in calculating diluted net income per share		47,195,898		46,882,383		47,068,563		46,960,226
Diluted net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock		165,000		325,626		337,575		325,626

INVESTMENT AT COST - On March 24, 2017, we acquired a 12.5% equity interest in Medic Vision – Imaging Solutions Ltd for $1.0 million. We also have an option to acquire an additional 12.5% equity interest for $1.4 million exercisable within one year from the initial share purchase date. Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. In accordance with ASC 325-20, Cost Method Investments, the investment is recorded at its cost of $1.0 million. No impairment in our investment was noted as of the quarter ended June 30, 2017.

INVESTMENT IN JOINT VENTURES – We have 14 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of June 30, 2017.

Joint venture investment and financial information

The following table is a summary of our investment in joint ventures during the quarter ended June 30, 2017 (in thousands):

Balance as of December 31, 2016	$	43,509
Equity in earnings in these joint ventures		4,922
Distribution of earnings		(3,993	)
Equity contributions in existing joint ventures		4,062
Balance as of June 30, 2016	$	48,500

We received management service fees from the centers underlying these joint ventures of approximately $3.5 million and $3.0 million for the quarters ended June 30, 2017 and 2016, respectively and $6.6 million and $5.9 million for the six months ended June 30, 2017 and 2016 respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.

The following table is a summary of key balance sheet data for these joint ventures as of June 30, 2017 and December 31, 2016 and income statement data for the six months ended June 2017 and 2016 (in thousands):

Balance Sheet Data:	June 30, 2017			December 31, 2016
Current assets	$	41,059		$	40,093
Noncurrent assets		106,421			100,146
Current liabilities		(16,342	)		(14,077	)
Noncurrent liabilities		(42,680	)		(44,405	)
Total net assets	$	88,458		$	81,757

Book value of RadNet joint venture interests	$	42,012		$	38,538
Cost in excess of book value of acquired joint venture interests		6,488			4,970
Total value of Radnet joint venture interests	$	48,500		$	43,509

Total book value of other joint venture partner interests	$	46,446		$	43,219

Income statement data for the six months ended June 30,	2017		2016
Net revenue	$	86,981	$	80,917
Net income	$	10,285	$	13,044

NOTE 3 – RECENT ACCOUNTING STANDARDS

In January 2017, the FASB issued ASU No. 2017-04 (“ASU 2017-04”), Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the current goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on the current Step 1). ASU 2017-04 is effective for annual and any interim impairment tests for periods beginning after December 15, 2019, with early adoption permitted. We are evaluating the effect of this guidance.

In January 2017, the FASB issued ASU No. 2017-01 (“ASU 2017-01”), Clarifying the Definition of a Business. ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is considered a business. ASU 2017-01 is effective for annual periods beginning after December 31, 2017 including interim periods within those periods. We are evaluating the effect of this guidance.

In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases, (Topic 842): Amendments to the FASB Accounting Standards Codification. ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The amendments in this update are effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018. Early adoption of the amendments is permitted for all entities. We are currently evaluating the impact this guidance will have on our consolidated financial statements, but expect this adoption will result in a significant increase in the assets and liabilities related to our leased properties and equipment.

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will become effective for the Company on January 1, 2018. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our statement of operations where the provision for bad debts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application.

NOTE 4 – FACILITY ACQUISITIONS AND DISPOSITIONS

Acquisitions

On June 1, 2017 we completed our acquisition of certain assets of Stockton MRI and Molecular Imaging Medical Center Inc., consisting of a multi-modality center located in Stockton, CA, for consideration of $4.4 million. The facility provides MRI, CT, Ultrasound, X-Ray and Nuclear Medicine services. We have made a fair value determination of the acquired assets and approximately $1.2 million of fixed assets and equipment, a $50,000 covenant not to compete, and $3.1 million of goodwill were recorded.

On May 3, 2017 we completed our acquisition of certain assets of D&D Diagnostics Inc., consisting of a single multi-modality imaging center located in Silver Spring, Maryland, for total purchase consideration of $2.4 million, including cash consideration of $1.2 million and settlement of liabilities of $1.2 million. We have made a fair value determination of the acquired assets and approximately $820,000 of fixed assets, $16,000 of other assets, and $1.5 million of goodwill were recorded. The facility provides MRI, CT, X-Ray and related services.

On February 1, 2017, we completed our acquisition of certain assets of MRI Centers, Inc., consisting of one single-modality imaging center located in Torrance, CA providing MRI and sports medicine services, for cash consideration of $800,000 and the payoff of $81,000 in debt. We have made a fair value determination of the acquired assets and approximately $289,000 of fixed assets, $9,800 of other assets, $100,000 covenant not to compete and $401,000 of goodwill were recorded.

On January 13, 2017, we completed our acquisition of certain assets of Resolution Medical Imaging Corporation for consideration of $4.0 million. The purchase of Resolution was enacted to contribute its assets to a joint venture with Cedars Sinai Medical Corporation which was effective April 1, 2017. See the joint venture formations section within this footnote for further information.

Dispositions

On April 28, 2017 we completed the sale of five imaging centers operating in Rhode Island to Rhode Island Medical Imaging, Inc. for approximately $4.5 million. We recorded a gain of approximately $1.9 million in the second quarter with regard to this transaction and have no remaining imaging centers in the state.

On April 1, 2017 we received from Cedars Sinai Medical Center $5.9 million representing a 25% noncontrolling interest in the West Valley Imaging Group, LLC (“WVI”). The determined net book value of the 25% interest was approximately $3.0 million. The proceeds in excess of the net book value, amounting to $1.8 million net of taxes, were recorded to equity in accordance with accounting guidance. RadNet exercises controlling financial interest and holds a 75% economic interest in WVI.

On April 1, 2017 we completed the sale of 2 wholly owned oncology practices to Cedars Sinai Medical Center in connection with the sale of non-controlling interest of the WVI subsidiary described above for approximately $1.2 million. We recorded a gain of approximately $361,000 on this transaction.

Joint venture formations:

On April 1, 2017 we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Total agreed contribution was $2.7 million of cash and assets with RadNet contributing $1.1 million for a 40% economic interest and CSMC contributing $1.6 million for a 60% economic interest. For its contribution, RadNet transferred $80,000 in cash and the net assets acquired in the acquisition of Resolution imaging of $2.5 million. CSMC contributed $120,000 in cash and paid RadNet $1.5 million for the Resolution imaging assets transferred to the venture. RadNet does not have controlling economic interest in SMIG and the investment is accounted for via the equity method.

On January 6, 2017, Image Medical Inc., a wholly owned subsidiary of RadNet, acquired a 49% economic interest ScriptSender, LLC, a partnership held by two individuals which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. Image Medical will contribute $3.0 million to the partnership for its 49% ownership stake over a three year period representing the maximum risk in the venture. As of June 30, 2017, the carrying amount of the investment is $2.8 million. We determined that ScriptSender, LLC is a VIE but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

NOTE 5 – REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES

Revolving credit facility, notes payable, and capital lease obligations:

As of the six months ended June 30, 2017 our debt obligations consist of the following (in thousands):

	June 30,			December 31,
	2017			2016

First Lien Term Loans		466,813			478,938

Second Lien Term Loans		168,000			168,000

Discounts on term loans		(15,915	)		(16,783	)

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019		787			980

Equipment notes payable at interest rates ranging from 3.3% to 5.6%, due through 2020, collateralized by medical equipment		269			341

Obligations under capital leases at interest rates ranging from 2.5% to 10.8%, due through 2022, collateralized by medical and office equipment		9,015			7,256
Total debt obligations		628,969			638,732
Less: current portion		(27,317	)		(26,557	)
Long term portion debt obligations	$	601,652		$	612,175

Term Loans, Revolving Credit Facility and Financing Activity Information:

At June 30, 2017, our credit facilities were comprised of two tranches of term loans (“First Lien Term Loans” and “Second Lien Term Loans”) and a revolving credit facility of $117.5 million (the “Revolving Credit Facility”). As of June 30, 2017, we were in compliance with all covenants under our credit facilities.

Included in our consolidated balance sheets at June 30, 2017 are $618.9 million of senior secured term loan debt (net of unamortized discounts of $15.9 million), broken down by loan agreement as follows (in thousands):

	Face Value		Discount			Total Carrying Value
First Lien Term Loans	$	466,813	$	(14,089	)	$	452,724
Second Lien Term Loans	$	168,000	$	(1,826	)	$	166,174
Total	$	634,813	$	(15,915	)	$	618,898

Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.

The following describes our 2017 financing activities:

Fourth Amendment to First Lien Credit Agreement

On February 2, 2017, we entered into Amendment No. 4 (the “Fourth Amendment”) to our Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended from time to time, the “First Lien Credit Agreement”). Pursuant to the Fourth Amendment, the interest rate charged for the applicable margin on the first lien term loans and the revolving credit facility was reduced by 50 basis points, from 3.75% to 3.25%. The minimum LIBOR rate underlying the first lien term loans remains at 1.0%. Except for such reduction in the interest rate on credit extensions, the Fourth Amendment did not result in any other material modifications to First Lien Credit Agreement. RadNet incurred expenses for the transaction in the amount of $543,000, which was recorded to discount on debt and will be amortized over the remaining term of the agreement.

The following describes our prior applicable financing activities:

Restatement Amendment and the First Lien Credit Agreement

On July 1, 2016, (the “Restatement Effective Date”), we entered into Amendment No. 3 to Credit and Guaranty Agreement (the “Restatement Amendment”) pursuant to which we amended and restated our then existing First Lien Credit Agreement. Pursuant to the First Lien Credit Agreement, we have issued $485 million of senior secured term loans (the “First Lien Term Loans”) and established a $117.5 million senior secured revolving credit facility (the “Revolving Credit Facility”). Prior to the Restatement Effective Date, our first lien credit facilities consisted of a Credit and Guaranty Agreement that we entered into on October 10, 2012 (the “Original First Lien Credit Agreement”), as subsequently amended by a first amendment dated April 3, 2013 (the “2013 Amendment”), a second amendment dated March 25, 2014 (the “2014 Amendment”), and a joinder agreement dated April 30, 2015 (the “2015 Joinder” and collectively with the Original First Lien Credit Agreement, the 2013 Amendment and the 2014 Amendment, the “Prior First Lien Credit Agreement”). The First Lien Credit Agreement increased the aggregate principal amount of First Lien Term Loans to $485.0 million and increased the Revolving Credit Facility to $117.5 million. Proceeds from the First Lien Credit Agreement were used to repay the previously outstanding first lien loans under the Prior First Lien Credit Agreement, make a $12.0 million principal payment of the Second Lien Term Loans (as described below), pay costs and expenses related to the First Lien Credit Agreement and provide approximately $10.0 million for general corporate purposes.

Interest. The interest rates payable on the First Lien Term Loans (after giving effect to the Fourth Amendment described above) are (a) the Adjusted Eurodollar Rate (as defined in the First Lien Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the First Lien Credit Agreement) plus 2.25% per annum. As applied to the First Lien Term Loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The three month Adjusted Eurodollar Rate at June 30, 2017 was 1.30%.

Payments. The scheduled quarterly principal payments of the First Lien Term Loans are approximately $6.1 million, with the balance due at maturity. Prior to the Restatement Amendment, the quarterly principal payments on the first lien term loans under the Prior First Lien Credit Agreement were approximately $6.2 million.

Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise, and (iii) September 25, 2020 if our indebtedness under the Second Lien Credit Agreement has not been repaid, refinanced or extended prior to such date.

Incremental Feature: Under the First Lien Credit Agreement, we can elect to request 1) an increase to the existing Revolving Credit Facility and/or 2) additional First Lien Term Loans, provided that the aggregate amount of such increases or additions does not exceed (A) an amount not in excess of $100.0 million minus any incremental loans requested under the similar provisions of the Second Lien Credit Agreement or (B) if the First Lien Leverage Ratio would not exceed 3.50:1.00 after giving effect to such incremental facilities, an uncapped amount, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide any incremental commitment or loan.

Revolving Credit Facility: The First Lien Credit Agreement provides for a $117.5 million Revolving Credit Facility. The termination date of the Revolving Credit Facility is the earliest to occur of: (i) July 1, 2021, (ii) the date the Revolving Credit Facility is permanently reduced to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, which addresses voluntary commitment reductions, (iii) the date of the termination of the Revolving Credit Facility due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement, and (iv) September 25, 2020 if our indebtedness under the Second Lien Credit Agreement (described below) has not been repaid, refinanced or extended prior to such date. Amounts borrowed under the Revolving Credit Facility bear interest based on types of borrowings as follows (after giving effect to the Fourth Amendment described above): (i) unpaid principal on loans under the Revolving Credit Facility at the Adjusted Eurodollar Rate (as defined in the First Lien Credit Agreement) plus 3.25% per annum or the Base Rate (as defined in the First Lien Credit Agreement) plus 2.25% per annum, (ii) letter of credit fees at 3.25% per annum and fronting fees for letters of credit at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement, and (iii) commitment fee of 0.5% per annum on the unused revolver balance.

Second Lien Credit Agreement:

On March 25, 2014, we entered into a Second Lien Credit and Guaranty Agreement (as amended from time to time, the “Second Lien Credit Agreement”) pursuant to which we issued $180 million of secured term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans were used to redeem our 10 3/8% senior unsecured notes, due 2018, to pay the expenses related to the transaction and for general corporate purposes. On July 1, 2016, in conjunction with the restated First Lien Credit Agreement, a $12.0 million principal payment was made on the Second Lien Term Loans.

The Second Lien Credit Agreement provides for the following:

Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0%. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The three month Adjusted Eurodollar Rate at June 30, 2017 was 1.30%. The rate paid on the Second Lien Term Loan at June 30, 2017 was 8.15%.

Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.

Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) of the Second Lien Credit Agreement or events of default per section 8.01 of the Second Lien Credit Agreement.

NOTE 6 – STOCK-BASED COMPENSATION

Stock Incentive Plans

Options

We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (“the Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. As of June 30, 2017, we have reserved for issuance under the 2017 Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the 2017 Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over three to five years and expire five to ten years from the date of grant.

As of June 30, 2017, we had outstanding options to acquire 560,149 shares of our common stock, of which options to acquire 205,000 shares were exercisable. The following summarizes all of our option transactions for the six months ended June 30, 2017:

Outstanding Options Under the 2006 Plan	Shares		Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value

Balance, December 31, 2016		375,626	$6.82
Granted		184,523	6.30
Balance, June 30, 2017		560,149	6.65	5.79	$	793,610
Exercisable at June 30, 2017		205,000	7.51	0.43		228,400

Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on June 30, 2017 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on June 30, 2017. No options were exercised during the six months ended June 30, 2017. As of June 30, 2017, total unrecognized stock-based compensation expense related to non-vested employee awards was $919,897 which is expected to be recognized over a weighted average period of approximately 3.1 years.

Restricted Stock Awards (“RSA’s”)

The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of June 30, 2017, we have issued a total of 4,945,460 RSA’s of which 470,351 were unvested at June 30, 2017. The following summarizes all unvested RSA’s activities during the six months ended June 30, 2017:

				Weighted-Average
				Remaining
				Contractual		Weighted-Average
	RSA's			Term (Years)		Fair Value
RSA's unvested at December 31, 2016		573,145				$6.18
Changes during the period
Granted		681,448				$5.98
Vested		(784,242	)			$6.02
RSA's unvested at June 30, 2017		470,351			0.86	$6.12

We determine the fair value of all RSA’s based of the closing price of our common stock on award date.

Other stock bonus awards

The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the six months ended June 30, 2017 we issued 10,000 shares relating to these awards, amounting to $59,000 of compensation expense

Plan summary

In sum, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at June 30, 2017, we had issued 13,044,359 total shares between options, RSA’s and other stock awards. With options cancelled and RSA’s forfeited amounting to 2,975,009 and 59,053 shares, respectively, there remain 3,989,703 shares available under the Restated Plan for future issuance.

NOTE 7 – SUBSEQUENT EVENTS

On July 1, 2017 our wholly owned subsidiary, Advanced Imaging Partners, Inc, sold a 25% noncontrolling interest in one of its imaging centers located in Timonium, Maryland to the University of Maryland St. Joseph Medical Center for $3.9 million.

On August 7, 2017 we acquired Diagnostic Imaging Associates (“DIA”) for $13.0 million in cash and $1.5 million in RadNet common stock. Located in the state of Delaware, DIA operates seven multimodality imaging centers and provides MRI, CT, Ultrasound, Mammography and X-Ray services.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this quarterly report.

Forward-Looking Statements

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.

In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Statements in this quarterly report concerning our ability to successfully acquire and integrate new operations, to grow our contract management business, our financial guidance, our future cost saving efforts, our increased business from new equipment or operations and our ability to finance our operations and repay our outstanding indebtedness, including our increased amortization payments, are forward-looking statements.

Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the factors included in “Risk Factors,” in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended or supplemented by the information in Part II– Item 1A below. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.

These forward-looking statements speak only as of the date when they are made. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Overview

We seek to develop leading positions in regional markets in order to leverage operational efficiencies. Our scale and density within selected geographies provides close, long-term relationships with key payors, radiology groups and referring physicians. Each of our facility managers is responsible for managing relationships with local physicians and payors, meeting our standards of patient service and maintaining profitability. We provide corporate training programs, standardized policies and procedures and sharing of best practices among the physicians in our regional networks.

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. For the six months ended June 30, 2017 and 2016, we performed 3,095,613 and 3,063,359 diagnostic imaging procedures, respectively, and generated total net revenue of $459.0 million and $435.0 million, respectively.

We have determined that BRMG and the NY Groups are VIEs, and that we are the primary beneficiary, and consequently, we consolidate the revenue and expenses, assets and liabilities of each. BRMG and the NY Groups on a combined basis recognized $33.5 million and $33.0 million of revenue, net of management service fees to RadNet, for the three months ended June 30, 2017 and 2016, respectively, and $33.5 million and $33.0 million of operating expenses for the three months ended June 30, 2017 and 2016, respectively. RadNet recognized in its condensed consolidated statement of operations $108.2 million and $104.1 million of net revenues for the three months ended June 30, 2017, and 2016 respectively, for management services provided to BRMG and the NY Groups relating primarily to the technical portion of total billed revenue.

We typically experience some seasonality to our business. During the first quarter of each year we generally experience the lowest volumes of procedures and the lowest level of revenue for any quarter during the year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients. As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.

Critical Accounting Policies

The Securities and Exchange Commission defines critical accounting estimates as those that are both most important to the portrayal of a company’s financial condition and results of operations and require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2016, as amended, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.

Use of Estimates

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements that were prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Management makes estimates and assumptions when preparing financial statements. These estimates and assumptions affect various matters, including:

our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements;

our disclosure of contingent assets and liabilities at the dates of the financial statements; and

our reported amounts of net revenue and expenses in our consolidated statements of operations during the reporting periods.

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could differ materially from these estimates.

During the period covered in this report, there were no material changes to the critical accounting estimates we use, and have described in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended.

Revenues

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. As it relates to BRMG and the NY Groups centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Groups as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Groups. As it relates to non-BRMG and NY Groups centers, namely the affiliated physician groups, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Service fee revenues are recorded during the period the services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances are based on historical collection rates of payor reimbursement contract agreements. We also record a provision for doubtful accounts based primarily on historical collection rates from related to patient copayments and deductible amounts for patients who have health care coverage under one of our third-party payors.

Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Commercial insurance	$	142,691		$	134,962		$	283,683		$	266,439
Medicare		47,611			45,558			95,291			91,385
Medicaid		6,525			6,890			13,259			13,915
Workers' compensation/personal injury		8,867			8,966			17,925			18,485
Other⁽¹⁾		8,362			7,383			16,648			14,377
Service fee revenue, net of contractual allowances and discounts		214,056			203,759			426,806			404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue	$	230,014		$	218,565		$	459,027		$	434,953

_______________________

⁽¹⁾ Other consists of revenue from teleradiology services, consulting fees and software revenue.

Provision for Bad Debts

We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by the historical payment patterns of each type of payor, write-off trends, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

Accounts Receivable

Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

Depreciation and Amortization of Long-Lived Assets

We depreciate our long-lived assets over their estimated economic useful lives with the exception of leasehold improvements where we use the shorter of the assets useful lives or the lease term of the facility for which these assets are associated.

Deferred Tax Assets

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

Valuation of Goodwill and Indefinite Lived Intangibles

Goodwill at June 30, 2017 totaled $244.5 million. Indefinite Lived Intangible Assets at June 30, 2017 totaled $7.9 million and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. Management evaluates goodwill and trade name intangibles, at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit’s carrying amount, including goodwill, to the fair value of the reporting unit. The fair value of a reporting unit is estimated using a combination of the income or discounted cash flows approach and the market approach, which uses comparable market data. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and a second step is performed to measure the amount of impairment loss, if any. Impairment of trade name intangibles is tested at the subsidiary level by comparing the subsidiary’s trade name carrying amount to its respective fair value. We tested both goodwill and trade name intangibles for impairment on October 1, 2016, noting no impairment, and have not identified any indicators of impairment through June 30, 2017.

Long-Lived Assets

We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment whenever indicators of impairment exist. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment were identified with respect to our long-lived assets as of June 30, 2017.

Recent Accounting Standards

Results of Operations

The following table sets forth, for the periods indicated, the percentage that certain items in the statements of operations bears to revenue, net of contractual allowances and discounts and inclusive of revenue under capitation contracts.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
NET REVENUE
Service fee revenue, net of contractual allowances and discounts		88.5%		88.2%		88.5%		88.4%
Provision for bad debts		-4.9%		-5.3%		-4.9%		-4.9%
Net service fee revenue		83.6%		82.9%		83.6%		83.5%
Revenue under capitation arrangements		11.5%		11.8%		11.5%		11.6%
Total net revenue		95.1%		94.7%		95.1%		95.1%
OPERATING EXPENSES
Cost of operations, excluding depreciation and amortization		82.0%		84.0%		83.7%		85.4%
Depreciation and amortization		6.9%		6.8%		6.9%		7.0%
Loss on sale and disposal of equipment		0.2%		0.2%		0.1%		0.1%
Severance costs		0.1%		0.1%		0.1%		0.1%
Total operating expenses		89.2%		91.2%		90.8%		92.6%


INCOME FROM OPERATIONS		5.9%		3.5%		4.3%		2.4%

OTHER INCOME AND EXPENSES
Interest expense		4.2%		4.7%		4.3%		4.7%
Meaningful use incentive		0.0%		0.0%		-0.1%		-0.6%
Equity in earnings of joint ventures		-1.2%		-1.4%		-1.0%		-1.2%
Gain on sale of imaging centers		-1.0%		0.0%		-0.5%		0.0%
Gain from return of common stock		0.0%		-2.2%		0.0%		-1.1%
Other expenses		0.0%		0.0%		0.0%		0.0%
Total other expenses		2.1%		1.1%		2.7%		1.8%


INCOME BEFORE INCOME TAXES		3.8%		2.4%		1.6%		0.7%
Provision for income taxes		-1.5%		-1.0%		-0.7%		-0.2%
NET INCOME		2.3%		1.5%		0.9%		0.5%
Net (loss) income attributable to noncontrolling interests		0.1%		-0.1%		0.1%		0.0%
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS		2.2%		1.6%		0.8%		0.5%

Three Months Ended June 30, 2017 Compared to the Three Months Ended June 30, 2016

Service Fee Revenue

Service fee revenue for the three months ended June 30, 2017 was $214.1 million compared to $203.8 million for the three months ended June 30, 2016, an increase of $10.3 million, or 5.1%.

Inclusive of only centers in operation over the second quarters of 2017 and 2016, service fee revenue increased $7.8 million or 3.8%. Of the total 3.8% period over period increase, higher 2017 reimbursement fee schedule rates combined with a boost in procedure volumes for MRI, CT, PET and tomography scans yielded 2.7% growth with the remaining 1.1% attributable a rise in management fee revenue for services provided to our joint venture and external business operations. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, service fee revenue from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $3.3 million. For the three months ended June 30, 2016, service fee revenue from centers that were acquired or divested subsequent to April 1, 2016 and excluded in the above comparison was $803,000.

Provision for Bad Debts

Provision for bad debts decreased $472,000, or 3.8%, to approximately $11.9 million, or 5.5% of service fee revenue, for the three months ended June 30, 2017 compared to $12.3 million, or 6.1% of service fee revenue, for the three months ended June 30, 2016. We review our provision by the application of judgment based on factors such as contractual reimbursement rates, payor mix, the age of receivables, historical cash collection experience and other relevant information.

Net Service Fee Revenue

Service fee revenue for the three months ended June 30, 2017 was $202.2 million compared to $191.4 million for the three months ended June 30, 2016, an increase of $10.8 million, or 5.6%.

Inclusive of only centers in operation over the second quarters of 2017 and 2016, net service fee revenue increased $7.5 million or 3.9%. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, net service fee revenue from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $3.6 million. For the three months ended June 30, 2016, service fee revenue from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $260,000.

Revenue Under Capitation Arrangements

Revenue under capitation arrangements for the three months ended June 30, 2017 was $27.8 million compared to $27.1 million for the three months ended June 30, 2016, an increase of $680,000 or 2.5%

Revenue under capitation arrangements, limited to centers which were in operation throughout the first quarters of 2017 and 2016 increased 927,000, or 3.5%. The increase relates to revenues from growth in insured members under existing capitation plans combined with an annualized rise in reimbursement rates. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, no amounts were excluded for revenue under capitation arrangements from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2016, revenue under capitation arrangements from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $249,000.

Operating Expenses

Cost of operations for the three months ended June 30, 2017 increased approximately $4.5 million, or 2.3%, from $194.1 million for the three months ended June 30, 2016 to $198.6 million for the three months ended June 30, 2017. The following table sets forth our cost of operations and total operating expenses for the three months ended June 30, 2017 and 2016 (in thousands):

	Three Months Ended June 30,
	2017		2016
Salaries and professional reading fees, excluding stock-based compensation	$	103,660	$	100,812
Stock-based compensation		1,038		1,028
Building and equipment rental		19,244		19,487
Medical supplies		11,968		12,808
Other operating expenses *		62,701		59,927
Cost of operations		198,611		194,062
Depreciation and amortization		16,612		15,811
Loss on sale and disposal of equipment		453		441
Severance costs		177		173
Total operating expenses	$	215,853	$	210,487

* Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses.

Salaries and professional reading fees, excluding stock-based compensation and severance

Salaries and professional reading fees increased $2.8 million, or 2.8%, to $103.7 million for the three months ended June 30, 2017 compared to $100.8 million for the three months ended June 30, 2016.

Salaries and professional reading fees, limited to only those centers which were in operation throughout the second quarters of both 2017 and 2016, increased $3.2 million, or 3.3%. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, salaries and professional reading fees from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $2.2 million. For the three months ended June 30, 2016, salaries and professional reading fees from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $2.6 million.

Stock-based compensation

Stock-based compensation was $1.0 million for each of the three months ended June 30, 2017 and June 30, 2016.

Building and equipment rental

Building and equipment rental expenses decreased $243,000 or 1.3%, to $19.2 million for the three months ended June 30, 2017 compared to $19.5 million for the three months ended June 30, 2016.

Building and equipment rental expenses increased $247,000 or 1.3% for only centers which were in operation throughout the second quarters of both 2017 and 2016. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, building and equipment rental expenses from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $299,000. For the three months ended June 30, 2016, building and equipment rental expenses from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $789,000.

Medical supplies

Medical supplies expense decreased $840,000, or 6.6%, to $12.0 million for the three months ended June 30, 2017 compared to $12.8 million for the three months ended June 30, 2016.

Medical supplies expenses, including only those centers which were in operation throughout the second quarters of both 2017 and 2016, increased $528,000 or 4.9%. Higher cost of contrast imaging agents administered during advanced modality procedures was primarily responsible for the increase. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, medical supplies expenses from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $572,000. For the three months ended June 30, 2016, medical supplies expenses from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $1.9 million.

Other operating expenses

Other operating expenses increased $2.8 million, or 4.6%, to $62.7 million for the three months ended June 30, 2017 compared to $59.9 million for the three months ended June 30, 2016.

Other operating expenses rose $4.0 million or 6.8% for only centers which were in operation throughout the second quarters of both 2017 and 2016. This 6.8% increase primarily relates to increased professional services and outside legal fees. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, other operating expense from centers that were acquired or divested subsequent April 1, 2016 and excluded from the above comparison was approximately $929,000. For the three months ended June 30, 2016, other operating expenses from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $2.1 million.

Depreciation and amortization

Depreciation and amortization increased $801,000, or 5.1%, to $16.6 million for the three months ended June 30, 2017 compared to $15.8 million for the three months ended June 30, 2016.

Depreciation and amortization, limited to centers which were in operation throughout the second quarters of both 2017 and 2016, increased $968,000, or 6.3%. The 6.3% increase relates to increased depreciation expense stemming from recent company investments in digital radiology equipment, MRI and CT units, and infrastructure improvements to existing centers. This comparison excludes expenses from centers that were acquired or divested subsequent to April 1, 2016. For the three months ended June 30, 2017, depreciation expense from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $248,000. For the three months ended June 30, 2016, depreciation expense from centers that were acquired or divested subsequent to April 1, 2016 and excluded from the above comparison was $415,000.

Loss on sale and disposal of equipment

We recorded a loss on sale of equipment of approximately $453,000 for the three months ended June 30, 2017 and approximately $441,000 for the three months ended June 30, 2016.

Interest expense

Interest expense for the three months ended June 30, 2017 decreased approximately $442,000, or 4.1%, to $10.3 million for the three months ended June 30, 2017 compared to $10.7 million for the three months ended June 30, 2016. Interest expense included $829,000 and $1.4 million of non-cash amortization for the three months ended June 30, 2017 and June 30, 2016, respectively. Excluding these non-cash amounts for each period, interest expense increased approximately $94,000 for the three months ended June 30, 2017 compared to the three months ended June 30, 2016. This increase was primarily due to premium payments on the interest rate cap agreements. See Derivative Instruments section of Note 2 to the consolidated condensed financial statements contained herein for more details on our derivative transactions.

Equity in earnings from unconsolidated joint ventures

For the three months ended June 30, 2017, we recognized equity in earnings from unconsolidated joint ventures of $3.0 million against $3.3 million earned over the same period ended June 30, 2016.

Gain on sale of imaging centers

We recognized a gain on the sale of 5 wholly owned imaging centers to the Rhode Island Medical Imaging, Inc. of approximately $1.9 million and a gain of $361,000 on the sale of two oncology practices to Cedars Sinai Medical Center for the three months ended June 30, 2017.

Provision for income taxes

We had an income tax expense for the three months ended June 30, 2017 of $3.5 million or 38.5% of income before income taxes, compared to the three months ended June 30, 2016 of an income tax expense of $2.3 million or 40.0% of the income before income taxes. The effective tax rate decreased by 1.5% due to the lack of stock compensation exercises in the current quarter.

Six Months Ended June 30, 2017 Compared to the Six Months Ended June 30, 2016

Service Fee Revenue

Service fee revenue for the six months ended June 30, 2017 was $426.8 million compared to $404.6 million for the six months ended June 30, 2016, an increase of $22.2 million, or 5.5%.

Service fee revenue, inclusive of only those centers in operation throughout the first two quarters of both 2017 and 2016, increased $18.7 million or 4.8%. The overall 4.8% increase was precipitated by a 3.7% combined hike in volumes in advanced imaging modalities at the higher 2017 fee schedule reimbursement rates plus a 1.1% revenue increase on digital tomography procedures. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, service fee revenue from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $16.7 million. For the six months ended June 30, 2016, service fee revenue from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $13.2 million.

Provision for Bad Debts

Provision for bad debts increased $870,000, or 3.8%, to approximately $23.5 million, or 5.5% of service fee revenue, for the six months ended June 30, 2017 compared to $22.6 million, or 5.6% of service fee revenue, for the six months ended June 30, 2016. We review our provision by the application of judgment based on factors such as contractual reimbursement rates, payor mix, the age of receivables, historical cash collection experience and other relevant information.

Net Service Fee Revenue

Net service fee revenue for the six months ended June 30, 2017 was $403.3 million compared to $382.0 million for the six months ended June 30, 2016, an increase of $21.3 million, or 5.6%.

Net service fee revenue, inclusive of only those centers in operation throughout the first two quarters of both 2017 and 2016, increased $17.7 million or 4.8%. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $15.6 million. For the six months ended June 30, 2016, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $12.0 million.

Revenue Under Capitation Arrangements

Revenue under capitation arrangements for the six months ended June 30, 2017 was $55.7 million compared to $53.0 million for the six months ended June 30, 2016, an increase of $2.7 million or 5.2%.

Revenue under capitation arrangements, limited to centers which were in operation throughout the first two quarters of 2017 and 2016 increased $3.1, or 5.8%. The increase relates to revenues from growth in insured members under existing capitation plans combined with an annualized rise in reimbursement rates. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, no amounts were excluded for revenue under capitation arrangements from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2016, capitation revenue from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was approximately $350,000.

Operating Expenses

Cost of operations for the six months ended June 30, 2017 increased approximately $13.2 million, or 3.4%, from $390.1 million for the six months ended June 30, 2016 to $404.1 million for the six months ended June 30, 2017. The following table sets forth our cost of operations and total operating expenses for the six months ended June 30, 2015 and 2014 (in thousands):

	Six Months Ended June 30,
	2017		2016
Salaries and professional reading fees, excluding stock-based compensation	$	211,931	$	205,284
Stock-based compensation		4,314		3,761
Building and equipment rental		38,810		38,666
Medical supplies		24,327		25,429
Other operating expenses *		124,683		117,748
Cost of operations		404,065		390,888
Depreciation and amortization		33,266		32,223
Loss on sale and disposal of equipment		408		441
Severance costs		380		340
Total operating expenses	$	438,119	$	423,892

* Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses.

Salaries and professional reading fees, excluding stock-based compensation and severance

Salaries and professional reading fees increased $6.6 million, or 3.2%, to $211.9 million for the six months ended June 30, 2017 compared to $205.3 million for the six months ended June 30, 2016.

Salaries and professional reading fees, limited to only centers which were in operation throughout the first two quarters of 2017 and 2016, increased $6.5 million or 3.3%. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $8.7 million. For the six months ended June 30, 2016, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was approximately $8.6 million.

Stock-based compensation

Stock-based compensation increased $553,000, or 14.7%, to approximately $4.3 million for the six months ended June 30, 2017 compared to $3.8 million for the six months ended June 30, 2016. This increase was driven by the higher fair value of RSA’s awarded and vested in the first six months of 2017 as compared to RSA’s awarded and vested in the same period in 2016.

Building and equipment rental

Building and equipment rental expenses increased $144,000, or 0.4%, to $38.8 million for the six months ended June 30, 2017 compared to $38.7 million for the six months ended June 30, 2016.

Building and equipment rental expenses, for only those centers which were in operation throughout the first and second quarters of 2017 and 2016, increased $554,000 or 1.5%. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $1.5 million. For the six months ended June 30, 2016, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was approximately $1.9 million.

Medical supplies

Medical supplies expense decreased $1.1 million, or 4.3%, to $24.3 million for the six months ended June 30, 2017 compared to $25.4 million for the six months ended June 30, 2016.

Medical supplies expenses, including only those centers which were in operation throughout the first and second quarters of both 2017 and 2016, increased $762,000, or 3.6%. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, medical supplies expenses from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $2.5 million. For the six months ended June 30, 2016, medical supplies expense from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $4.4 million.

Other operating expenses

Other operating expenses increased $6.9 million, or 5.9%, to $124.7 million for the six months ended June 30, 2017 compared to $117.7 million for the six months ended June 30, 2016.

Other operating expenses, limited to centers which were in operation throughout the first and second quarters of both 2017 and 2016, increased $7.2 million, or 6.3%. This 6.3% increase was primarily generated from higher utility rates, legal services expenses and billing fees related to the installment of a new billing system. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, other operating expense from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $3.7 million. For the six months ended June 30, 2016, other operating expense from centers that were acquired or divested subsequent to January 1, 2016 was $3.9 million.

Depreciation and amortization

Depreciation and amortization increased $1.0 million, or 3.2%, to $33.3 million for the six months ended June 30, 2017 compared to $32.2 million for the six months ended June 30, 2016.

Depreciation and amortization, including only those centers which were in operation throughout the first and second quarters of both 2017 and 2016, increased $1.1 million, or 3.6%. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2016. For the six months ended June 30, 2017, depreciation expense from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $1.1 million. For the six months ended June 30, 2016, depreciation and amortization from centers that were acquired or divested subsequent to January 1, 2016 and excluded from the above comparison was $1.2 million.

Loss on sale and disposal of equipment

We recorded a loss on sale of equipment of approximately $408,000 for the six months ended June 30, 2017 and approximately $441,000 for the six months ended June 30, 2016.

Interest expense

Interest expense for the six months ended June 30, 2017 decreased approximately $883,000, or 4.1%, to $20.5 million for the six months ended June 30, 2017 compared to $21.4 million for the six months ended June 30, 2016. Interest expense included $1.7 million and $2.7 million of non-cash amortization for the six months ended June 30, 2017 and June 30, 2016, respectively. Excluding these non-cash amounts for each period, interest expense increased approximately $185,000 for the six months ended June 30, 2017 compared to the six months ended June 30, 2016. This increase was primarily due to premium payments on the interest rate cap agreements. See Derivative Instruments section of Note 2 to the consolidated condensed financial statements contained herein for more details on our derivative transactions.

Meaningful use incentive

For the six months ended June 30, 2017 and June 30, 2016, we recognized other income from meaningful use incentive in the amount of $250,000 and $2.8 million, respectively. These amounts were earned under a Medicare program to promote the use of electronic health record technology. See Note 1 to the condensed consolidated financial statements contained herein for more detail regarding this meaningful use incentive.

Equity in earnings from unconsolidated joint ventures

For the six months ended June 30, 2017 we recognized equity in earnings from unconsolidated joint ventures of $4.9 million versus $5.6 million for the six months ended June 30, 2016, a decrease of $631,000 or 11.4%.

Gain on sale of imaging centers

During the six months ended June 30, 2017, we recognized a gain on the sale of 5 wholly owned imaging centers to the Rhode Island Medical Imaging, Inc. of approximately $1.9 million and a gain of $361,000 on the sale of two oncology practices to Cedars Sinai Medical Center.

Gain from return of common stock

For the six months ended June 30, 2016, we recorded a gain on return of common stock of $5.0 million.

Provision for income taxes

We had a tax provision for the six months ended June 30, 2017 of $3.1 million or 39.2% of income before income taxes, compared to a tax provision for the six months ended June 30, 2016 of $750,000 or 24.8% of income before income taxes. The effective tax rate was lower in the six months ended June 30, 2016 due to the effect of disqualifying dispositions of Incentive Stock Options.

Adjusted EBITDA

We use both GAAP and non-GAAP metrics to measure our financial results. One non-GAAP measure we believe assists us is Adjusted EBITDA. We believe that, in addition to GAAP metrics, these non-GAAP metrics assist us in measuring our cash generated from operations and ability to service our debt obligations. We believe this information is useful to investors and other interested parties because we are highly leveraged and our non-GAAP metrics remove non-cash and certain other charges that occur in the affected period and provide a basis for measuring the Company's financial condition against other quarters.

We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and exclude losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period.

Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

Adjusted EBITDA is most comparable to the GAAP financial measure, net income (loss) attributable to RadNet, Inc. common stockholders. The following is a reconciliation of GAAP net income (loss) attributable to RadNet, Inc. common stockholders to Adjusted EBITDA for the three months ended June 30, 2017 and 2016, respectively.

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Net income attributable to RadNet, Inc. common stockholders	$	5,310		$	3,622		$	4,100		$	2,225
Plus provision for income taxes		3,523			2,256			3,065			750
Plus other expenses		7			4			10			6
Less gain on sale of imaging centers		(2,301	)		–			(2,301	)		–
Less gain on return of common stock		–			(5,032	)		–			(5,032	)
Plus expenses of divested/closed operations		1,200			–			1,200			–
Plus acquisition related working capital adjustment		–			6,072			–			6,072
Plus interest expense		10,303			10,745			20,543			21,426
Plus severance costs		177			173			380			340
Plus loss on sale and disposal of equipment		453			441			408			441
Plus reimbursable legal expenses		723			–			723			–
Plus depreciation and amortization		16,612			15,811			33,266			32,223
Plus non-cash employee stock-based compensation		1,038			1,028			4,314			3,761
Adjusted EBITDA	$	37,045		$	35,120		$	65,708		$	62,212

Liquidity and Capital Resources

We had cash and cash equivalents of $12.7 million and accounts receivable of $170.2 million at June 30, 2017, compared to cash and cash equivalents of $20.6 million and accounts receivable of $164.2 million at December 31, 2016. We had a working capital balance of $55.9 million and $62.6 million at June 30, 2017 and December 31, 2016, respectively. We had net income attributable to RadNet, Inc. common stockholders for the three months ended June 30, 2017 and 2016 of $5.3 million and $3.6 million respectively. We had net income attributable to RadNet, Inc. common stockholders for the six months ended June 30, 2017 and June 30, 2016 of $4.1 million and $2.2 million respectively. We also had stockholders’ equity of $63.6 million and $52.1 million at June 30, 2017 and December 31, 2016, respectively.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Our $117.5 million revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017. Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

We and our subsidiaries or affiliates may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.

Sources and Uses of Cash

Cash provided by operating activities was $50.2 million and $51.4 million for the six months ended June 30, 2017 and June 30, 2016, respectively.

Cash used in investing activities was $46.0 million and $46.5 million for the six months ended June 30, 2017 and 2016, respectively. For the six months ended June 30, 2017, we purchased property and equipment for approximately $42.6 million, acquired imaging facilities for $9.9 million and received proceeds from the sale of imaging and oncology facilities of $5.6 million.

Cash used in financing activities was $12.1 million and $4.9 million for the six months ended June 30, 2017 and 2016, respectively. The cash used in financing activities for the six months ended June 30, 2017, was due to principal payments on our $466.8 million face value term loan, pay down on equipment notes and capital leases and $5.9 million in proceeds received for the sale of our 25% percent interest in West Valley Imaging, LLC. (See Notes 4 and 5 to the condensed consolidated financial statements herein).

As of June 30, 2017, we were in compliance with all covenants under the Original Credit Agreement (as amended by the 2013 Amendment, the 2014 Amendment, the 2015 Joinder, the 2016 Amendment and the 2017 Amendment) and the Second Lien Credit Agreement.

Included in our condensed consolidated balance sheet at June 30, 2017 is $618.9 million of senior secured term loan debt (net of unamortized discounts of $15.9 million), broken down by loan agreement as follows (in thousands):

	Face Value		Discount			Total Carrying Value
First Lien Term Loans	$	466,813	$	(14,089	)	$	452,724
Second Lien Term Loans	$	168,000	$	(1,826	)	$	166,174
Total	$	634,813	$	(15,915	)	$	618,898

The following describes our 2017 financing activities:

Fourth Amendment to First Lien Credit Agreement

The following describes our prior applicable financing activities:

Restatement Amendment and the First Lien Credit Agreement

Payments. The scheduled quarterly principal payments of the First Lien Term Loans is approximately $6.1 million, with the balance due at maturity. Prior to the Restatement Amendment, the quarterly principal payments on the first lien term loans under the Prior First Lien Credit Agreement were approximately $6.2 million.

Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i)July 1, 2023, (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise, and (iii) September 25, 2020 if our indebtedness under the Second Lien Credit Agreement has not been repaid, refinanced or extended prior to such date.

Second Lien Credit Agreement:

On March 25, 2014, we entered into a Second Lien Credit and Guaranty Agreement (as amended from time to time, the “Second Lien Credit Agreement”) pursuant to which we issued $180 million of secured term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans were used to redeem our 10 3/8% senior unsecured notes, due 2018, to pay the expenses related to the transaction and for general corporate purposes. On July 1, 2016, in conjunction with the Restatement Amendment, a $12.0 million principal payment was made on the Second Lien Term Loans.

The Second Lien Credit Agreement provides for the following:

Subsequent Events

On July 1, 2017 our wholly owned subsidiary, Advanced Imaging Partners, Inc., sold a 25% non-controlling interest in one of its imaging centers located in Timonium, Maryland to the University of Maryland St. Joseph Medical Center for $3.9 million.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Foreign Currency Exchange Risk. We receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.

We maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign currency exchange contracts to mitigate this risk. At June 30, 2017, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against the Canadian dollar and the Hungarian Forint would have resulted in an annual increase of approximately $31,000 in operating expenses.

Interest Rate Sensitivity We pay interest on various types of debt instruments to our suppliers and lending institutions. The agreements entail either fixed or variable interest rates. Instruments which have fixed rates are mainly leases on radiology equipment. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities. Accordingly, our interest expense and consequently, our earnings, are affected by changes in short term interest rates. However due to our purchase of caps, described below, the effects of interest rate changes are limited.

At June 30, 2017, we had $460.8 million outstanding subject to an adjusted Eurodollar election on First Lien Term Loans under the First Lien Credit Agreement and $168.0 million on Second Lien Term Loans under the Second Lien Credit Agreement. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the First Lien Term Loans and the Second Lien Credit Agreement.

To mitigate interest rate risk sensitivity, in the fourth quarter of 2016 we entered into two forward interest rate cap agreements (the “2016 Caps”) which were designated at inception as cash flow hedges of future cash interest payments. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. At June 30, 2017, 3 month LIBOR was 1.30%. The 2016 Caps are designed to provide a hedge against interest rate increases. The 2016 Caps have a notional amount of $150,000,000 and $350,000,000 and will mature in September and October 2020. We are liable for a $5.3 million premium to enter into the caps which is being accrued over the life of the 2016 Caps. See Note 2 to the consolidated financial statements contained herein.

A hypothetical 1% increase in the adjusted Eurodollar rates under the First Lien Credit Agreement and Second Lien Credit Agreement over the rates experienced in 2016 would, after considering the effects of the 2016 Caps, result in an increase of $6.3 million in annual interest expense and a corresponding decrease in income before taxes. At June 30, 2017, an additional $6.1 million in debt instruments is tied to the prime rate. A hypothetical 1% increase in the prime rate would result in an annual increase in interest expense of approximately $61,000 and a corresponding decrease in income before taxes. These amounts are determined by considering the impact of the hypothetical interest rates on the borrowing costs and cap agreements. These analyses do not consider the effects of the reduced level of overall economic activity that could exist in such an environment. Further, in the event of a change of such magnitude, our management would likely take actions to further mitigate its exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, the sensitivity analysis assumes no changes in our financial structure.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of June 30, 2017. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2017 because deficiencies in the design and operating effectiveness of several information technology dependent manual controls and certain information technology general controls (“ITGC’s”) related to the revenue and accounts receivable process caused a material weakness in our internal control over financial reporting as described in more detail below.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”). Internal control over financial reporting includes policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are transacted in accordance with authorizations of management and directors of the Company, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, conducted an assessment of the effectiveness of its internal control over financial reporting as of June 30, 2017 based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, management concluded that our internal control over financial reporting was not effective as of June 30, 2017 because of the material weakness described below.

A material weakness is defined as “a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.”

Our management initially identified certain control deficiencies in connection with the review of our controls at December 31, 2016 and concluded that, as of June 30, 2017, the following control deficiencies related to the Company’s revenue and accounts receivable process continue to aggregate to a material weakness in the Company’s internal control over financial reporting:

Certain information technology dependent manual controls which are (i) designed to ensure the completeness of revenue transaction processing, and (ii) designed to ensure a reasonable valuation of the Company’s accounts receivable balance were not performed timely, accurately or reviewed with sufficient precision

Certain user access, program change and operations control components of ITGCs pertaining to multiple systems which capture and bill revenue transactions were not operating effectively

The ineffective design and operation of these information technology dependent manual controls and ITGCs impacts a material portion of our revenue transactions. Our management is not aware of any material misstatement or inaccuracy in the financial statements included in this report.

Remediation Plan for Material Weakness

Our management, with oversight of our Audit Committee, has been actively engaged in developing a remediation plan to address the material weakness reported. During the quarter ended June 30, 2017, the Company continues to implement remediation efforts as follows:

Ensure that all revenue-related IT dependent manual controls are performed on a timely basis with a sufficient level of precision.

Continue our plan to streamline the number of systems with enhanced quality and functionality utilized by the Company for the capture and billing of revenue transactions

Implement effective user access controls across all revenue related systems to ensure proper user access and timely removal of terminated users, and improve documentation surrounding program change and information technology operations controls.

If the remedial measures described above are insufficient to address the material weakness described above, or are not implemented timely, or additional deficiencies arise in the future, material misstatements in our interim or annual financial statements may occur in the future and could have the effects described in “Item 1A. Risk Factors” in Part II of this Form 10-Q.

Changes in Internal Control over Financial Reporting

Except for the remediation efforts described above, management did not identify any change in internal control over financial reporting occurring during the quarter ended June 30, 2017 that materially affected, or was reasonably likely to materially affect, the Company’s internal control over financial reporting.

Inherent Limitations on Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of management override or improper acts, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to management override, error or improper acts may occur and not be detected. Any resulting misstatement or loss may have an adverse and material effect on our business, financial condition and results of operations.

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

We are engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of our business. We do not believe that the outcome of any of our current litigation will have a material adverse impact on our business, financial condition and results of operations. However, we could be subsequently named as a defendant in other lawsuits that could adversely affect us.

ITEM 1A. Risk Factors

For information about the risks and uncertainties related to our business, please see the risk factors described in our annual report on Form 10-K for the year ended December 31, 2016, as amended. The risks described in our Form 10-K, as amended, are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information

None.

ITEM 6. Exhibits

Reference is made to the Exhibit Index immediately following the signature page of this report on Form 10-Q.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADNET, INC.
	(Registrant)

Date: August 9, 2017	By:	/s/ Howard G. Berger, M.D.
		Howard G. Berger, M.D., President and Chief Executive Officer (Principal Executive Officer)


Date: August 9, 2017	By:	/s/ Mark D. Stolper
		Mark D. Stolper, Chief Financial Officer (Principal Financial and Accounting Officer)

INDEX TO EXHIBITS

	Exhibit Number		Description

	31.1		Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	31.2		Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1		Certification of Howard G. Berger, M.D. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

	32.2		Certification of Mark D. Stolper pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

	101.INS		XBRL Instance Document

	101.SCH		XBRL Schema Document

	101.CAL		XBRL Calculation Linkbase Document

	101.LAB		XBRL Label Linkbase Document

	101.PRE		XBRL Presentation Linkbase Document

	101.DEF		XBRL Definition Linkbase Document

This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-31.1 2 radnet_10q-ex3101.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Howard G. Berger, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of RadNet, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d –15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 9, 2017	/s/ Howard G. Berger, M.D.
	Howard G. Berger, M.D.
	President, Chief Executive Officer and Chairman of the Board of Directors
	(Principal Executive Officer)

EX-31.2 3 radnet_10q-ex3102.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark D. Stolper, certify that:

1. I have reviewed this quarterly report on Form 10-Q of RadNet, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 9, 2017	/s/ Mark D. Stolper
	Mark D. Stolper
	Executive Vice President and Chief Financial Officer
	(Principal Financial Officer)

EX-32.1 4 radnet_10q-ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017, as filed with the Securities and Exchange Commission on August 9, 2017 (the “Report”), I, Howard G. Berger, M.D., Chairman of the Board of Directors and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.

	/s/ Howard G. Berger, M.D.
	Howard G. Berger, M.D.
	Chairman, President and Chief Executive Officer
	(Principal Executive Officer)
	August 9, 2017

A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 radnet_10q-ex3202.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RadNet, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017, as filed with the Securities and Exchange Commission on August 9, 2017 (the “Report”), I, Mark D. Stolper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	/s/ Mark D. Stolper
	Mark D. Stolper
	Chief Financial Officer
	(Principal Financial Officer)
	August 9, 2017

A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 6 rdnt-20170630.xml XBRL INSTANCE FILE 0000790526 2017-01-01 2017-06-30 0000790526 2016-01-01 2016-06-30 0000790526 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-06-30 0000790526 rdnt:RadnetIncStockholdersEquityMember 2017-01-01 2017-06-30 0000790526 us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-06-30 0000790526 rdnt:ImpactOfAdoptionMember 2016-01-01 2016-06-30 0000790526 2017-08-04 0000790526 2017-06-30 0000790526 2016-12-31 0000790526 us-gaap:CommonStockMember 2017-06-30 0000790526 us-gaap:CommonStockMember 2016-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000790526 us-gaap:RetainedEarningsMember 2017-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2017-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000790526 us-gaap:RetainedEarningsMember 2016-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2016-12-31 0000790526 rdnt:RadnetIncStockholdersEquityMember 2017-06-30 0000790526 rdnt:RadnetIncStockholdersEquityMember 2016-12-31 0000790526 us-gaap:RestrictedStockMember 2017-06-30 0000790526 us-gaap:RestrictedStockMember 2016-12-31 0000790526 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000790526 rdnt:FutureServiceMember 2017-01-01 2017-06-30 0000790526 us-gaap:StockOptionMember 2017-01-01 2017-06-30 0000790526 rdnt:RestatedPlanMember 2017-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000790526 us-gaap:InterestRateContractMember 2017-01-01 2017-06-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0000790526 2015-12-31 0000790526 2016-06-30 0000790526 rdnt:ScriptSenderMember 2017-01-01 2017-06-30 0000790526 rdnt:FirstLienTermLoansMember 2017-06-30 0000790526 rdnt:SecondLienTermLoanMember 2017-06-30 0000790526 rdnt:SecondLienTermLoanMember 2016-12-31 0000790526 us-gaap:FairValueInputsLevel1Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel2Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel3Member 2017-06-30 0000790526 rdnt:TotalFairValueMember 2017-06-30 0000790526 us-gaap:FairValueInputsLevel1Member 2016-12-31 0000790526 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000790526 us-gaap:FairValueInputsLevel3Member 2016-12-31 0000790526 rdnt:TotalFairValueMember 2016-12-31 0000790526 rdnt:ResolutionImagingMedicalCorpMember 2017-01-01 2017-06-30 0000790526 rdnt:MRICentersOfTorranceMember 2017-01-01 2017-06-30 0000790526 rdnt:RestatedPlanMember 2017-01-01 2017-06-30 0000790526 us-gaap:InterestRateContractMember 2017-06-30 0000790526 rdnt:MRICentersIncMember 2017-01-01 2017-06-30 0000790526 rdnt:MRICentersIncMember 2017-06-30 0000790526 rdnt:FirstLienTermLoansMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0000790526 rdnt:FirstLienTermLoanMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:FirstLienTermLoanMember 2016-12-31 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:FirstLienTermLoansMember 2016-12-31 0000790526 rdnt:FirstLienTermLoansMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:FirstLienTermLoansMember 2016-12-31 0000790526 rdnt:TotalFairValueMember rdnt:FirstLienTermLoansMember 2017-06-30 0000790526 rdnt:TotalFairValueMember rdnt:FirstLienTermLoansMember 2016-12-31 0000790526 rdnt:TotalFaceValueMember rdnt:FirstLienTermLoansMember 2017-06-30 0000790526 rdnt:TotalFaceValueMember rdnt:FirstLienTermLoansMember 2016-12-31 0000790526 rdnt:SecondLienTermLoansMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel1Member rdnt:SecondLienTermLoansMember 2016-12-31 0000790526 rdnt:SecondLienTermLoansMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel2Member rdnt:SecondLienTermLoansMember 2016-12-31 0000790526 rdnt:SecondLienTermLoansMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0000790526 us-gaap:FairValueInputsLevel3Member rdnt:SecondLienTermLoansMember 2016-12-31 0000790526 rdnt:SecondLienTermLoansMember rdnt:TotalFairValueMember 2017-06-30 0000790526 rdnt:TotalFairValueMember rdnt:SecondLienTermLoansMember 2016-12-31 0000790526 rdnt:SecondLienTermLoansMember rdnt:TotalFaceValueMember 2017-06-30 0000790526 rdnt:TotalFaceValueMember rdnt:SecondLienTermLoansMember 2016-12-31 0000790526 rdnt:PropertyAndEquipmentMember 2017-01-01 2017-06-30 0000790526 us-gaap:LeaseholdImprovementsMember 2017-01-01 2017-06-30 0000790526 rdnt:September2020CapMember 2017-06-30 0000790526 rdnt:October2020CapMember 2017-06-30 0000790526 us-gaap:StockOptionMember 2016-12-31 0000790526 us-gaap:StockOptionMember 2017-06-30 0000790526 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0000790526 rdnt:MedicVisionMember 2017-06-30 0000790526 rdnt:MedicVisionMember 2017-01-01 2017-06-30 0000790526 2017-04-01 2017-06-30 0000790526 2016-04-01 2016-06-30 0000790526 us-gaap:InterestRateContractMember 2017-04-01 2017-06-30 0000790526 rdnt:SantaMonicaImagingGroupJVMember 2017-01-01 2017-06-30 0000790526 rdnt:DAndDDiagnosticsIncMember 2017-01-01 2017-06-30 0000790526 rdnt:StocktonMRIIncMember 2017-01-01 2017-06-30 0000790526 rdnt:HematologyOncologyMember 2017-01-01 2017-06-30 0000790526 rdnt:DAndDDiagnosticsIncMember 2017-06-30 0000790526 rdnt:StocktonMRIIncMember 2017-06-30 0000790526 rdnt:RhodeIslandMedicalImagingIncMember 2017-01-01 2017-06-30 0000790526 rdnt:SantaMonicaImagingMember 2017-01-01 2017-06-30 0000790526 rdnt:SantaMonicaImagingMember 2017-06-30 0000790526 rdnt:FirstLienTermLoansMember 2016-12-31 0000790526 rdnt:FourthFirstMember 2017-06-30 0000790526 rdnt:WestValleyImagingMember 2017-01-01 2017-06-30 0000790526 rdnt:OncologyPracticesMember 2017-01-01 2017-06-30 0000790526 rdnt:ScriptSenderMember 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure rdnt:Integer RadNet, Inc. 0000790526 10-Q 2017-06-30 false --12-31 No No Yes Accelerated Filer Q2 2017

4763000

2272000

4100000

663000

4100000

1949000

323000

5623000

3379000

47266352

0.0001

.0001

200000000

47266352

46574904

47266352

46574904

104000000

100000000

11200000

9000000

470351

573145

681448

784242

P10M10D

6.12

6.18

5.98

6.02

10000

184523

14000000

3989703

16648000

14377000

8362000

7383000

17925000 18485000 8867000 8966000

13259000

13915000

6525000

6890000

95291000 91385000 47611000 45558000

283683000

266439000

142691000

134962000

0.05

0.04

0.01

4100000

2225000

1902000

323000

5310000

3622000

3065000

750000

1073000

-323000

3523000

2256000

22000

-16000

20000

-20000

3063000

2256000

1933000

323000

4699000

3359000

663000

47000

313000

-243000

2400000

2209000

1886000

323000

4386000

3602000

-1722000

-944000

-1940000

-10000

-333000

323000

-7931000

-13000

2500000

3000000

2500000

634813000

466813000

168000000

15915000

14089000

1826000

618898000

452724000

166174000

466813000

168000000

478938000

-1970000

818000

919897000

P3Y1M6D

4945460 13044359

470351

2975009

59053

-1970000

PROVISION FOR BAD DEBTS - We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by the historical payment patterns of each type of payor, write-off trends, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

INVENTORIES - Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 30 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATION - Accounting for acquisitions requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.

1800000

2000000

9800

16000

401000

1500000

3100000

100000

50000

.40

0.49

468564000

483129000

468564000

483129000

466813000

478938000

169260000

167580000

169260000

167580000

168000000

27000

3 to 15 years

3 to 30 years

14000000

150000000

350000000

5300000

14 35% to 55%

375626

560149

205000

6.82

6.65

6.30

7.51

P5Y9M14D

P5M5D

793610

228400

1000000

.125

851820000

849476000

6298000

5733000

48416000

50356000

1806000

2004000

41506000

42682000

253179000

247725000

207651000

217914000

21702000

28435000

3087000

2428000

170155000

164210000

788171000

797423000

8290000

5108000

3632000

2730000

598020000

609445000

26429000

24799000

151800000

155341000

5384000

4526000

21933000

22031000

2991000

2961000

1961000

1516000

12079000

13141000

107452000

111166000

851820000

849476000

6733000

3567000

56916000

48486000

-146111000

-150211000

-1394000

306000

204417000

198387000

4000

20908000

11061000

14161000

8078000

438119000

423892000

215853000

210487000

380000

340000

177000

173000

-408000

-441000

-453000

-441000

33266000

32223000

16612000

15811000

404065000

390888000

198611000

194062000

459027000

434953000

230014000

218565000

55721000

52982000

27812000

27132000

403306000

381971000

202202000

191433000

23500000

22630000

11854000

12326000

426806000

404601000

214056000

203759000

13080000

8039000

5015000

2443000

-10000

-6000

-7000

-4000

4922000

5553000

2994000

3274000

250000 2808000 0 0

20543000

21426000

10303000

10745000

663000

47000

313000

-243000

7828000

3022000

9146000

5635000

0.09

0.05

0.11

0.08

0.09

0.05

0.11

0.08

47068563

46960226

47195898

46882383

46662420

46576631

46756276

46558944

50159000

51424000

7014000

10983000

445000

1830000 1052000

835000

-220000

-4553000

-8454000

29445000

24873000

4314000

3761000

1636000

2738000

3993000

2098000

23500000

22630000

12707000

20638000

446000

433000

22000

-16000

-12144000

-4874000

150000

139400000

221700000

139400000

235500000

4850000

655000

157000

570000

12125000

12357000

3769000

6310000

-45968000

-46547000

1473000

994000

63000

42647000

40267000

500000

9904000

6603000

80000

734000

19023000

18545000

17500000 15400000

5200000

1300000

3000000

125000 0 0 5032000 0 5032000

2301000

We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At June 30, 2017, we operated directly or indirectly through joint ventures with hospitals, 295 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.   The consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc. The consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.   Accounting Standards Codification (“ASC”) 810-10-15-14, Consolidation, stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.   Howard G. Berger, M.D., is our President and Chief Executive Officer, a member of our Board of Directors, and also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at nearly all of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups.    We contract with nine medical groups which provide professional medical services at all of our facilities in Manhattan and Brooklyn, New York. These contracts are similar to our contract with BRMG. Six of these groups are owned by John V. Crues, III, M.D., RadNet’s Medical Director, a member of our Board of Directors, and a 1% owner of BRMG. Dr Berger owns a controlling interest in two of these medical groups which provide professional medical services at one of our Manhattan facilities.    RadNet provides non-medical, technical and administrative services to BRMG and the nine medical groups mentioned above (“NY Groups”) for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations of BRMG and the NY Groups and we determine the annual budget of BRMG and the NY Groups. BRMG and the NY Groups both have insignificant operating assets and liabilities, and de minimis equity. Through the management agreement with us, all cash flows of BRMG and the NY Groups are transferred to us.     We have determined that BRMG and the NY Groups are VIE’s, and that we are the primary beneficiary, and consequently, we consolidate the revenue and expenses, assets and liabilities of each. BRMG and the NY Groups on a combined basis recognized $33.5 million and $33.0 million of revenue, net of management service fees to RadNet, for the three months ended June 30, 2017 and 2016, respectively, and $33.5 million and $33.0 million of operating expenses for the three months ended June 30, 2017 and 2016, respectively. RadNet recognized in its condensed consolidated statement of operations $108.2 million and $104.1 million of net revenues for the three months ended June 30, 2017, and 2016 respectively, for management services provided to BRMG and the NY Groups relating primarily to the technical portion of total billed revenue.   BRMG and the NY Groups on a combined basis recognized $69.0 million and $66.9 million of revenue, net of management service fees to RadNet, for the six months ended June 30, 2017 and 2016, respectively, and $69.0 million and $66.9 million of operating expenses for the six months ended June 30, 2017 and 2016, respectively. RadNet recognized in its condensed consolidated statement of operations $221.5 million and $208.0 million of net revenues for the six months ended June 30, 2017, and 2016 respectively, for management services provided to BRMG and the NY Groups relating primarily to the technical portion of total billed revenue.   The cash flows of BRMG and the NY Groups are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at June 30, 2017 and December 31, 2016, we have included approximately $104.0 million and $100.0 million, respectively, of accounts receivable and approximately $11.2 million and $9.0 million of accounts payable and accrued liabilities related to BRMG and the NY Groups.   The creditors of BRMG and the NY Groups do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of BRMG and the NY Groups. However, both BRMG and the NY Groups are managed to recognize no net income or net loss and, therefore, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.    At all of our centers we have entered into long-term contracts with radiology groups in the area to provide physician services at those facilities. These radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. In these facilities, we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the value of the services we provide. Except in New York City, the fee is based on the practice group’s professional revenue, including revenue derived outside of our diagnostic imaging centers. In New York City we are paid a fixed fee set in advance for our services. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us and we have no financial controlling interest in the radiology practices. Because of the controlling relationship of Dr. Berger and Dr. Crues in the California and New York City practices as stated in detail above, we consolidate the revenue and expenses.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended June 30, 2017 and 2016 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2016, as amended.

Acquisitions   On June 1, 2017 we completed our acquisition of certain assets of Stockton MRI and Molecular Imaging Medical Center Inc., consisting of a multi-modality center located in Stockton, CA, for consideration of $4.4 million. The facility provides MRI, CT, Ultrasound, X-Ray and Nuclear Medicine services. We have made a fair value determination of the acquired assets and approximately $1.2 million of fixed assets and equipment, a $50,000 covenant not to compete, and $3.1 million of goodwill were recorded.   On May 3, 2017 we completed our acquisition of certain assets of D&D Diagnostics Inc., consisting of a single multi-modality imaging center located in Silver Spring, Maryland, for total purchase consideration of $2.4 million, including cash consideration of $1.2 million and settlement of liabilities of $1.2 million. We have made a fair value determination of the acquired assets and approximately $820,000 of fixed assets, $16,000 of other assets, and $1.5 million of goodwill were recorded. The facility provides MRI, CT, X-Ray and related services.   On February 1, 2017, we completed our acquisition of certain assets of MRI Centers, Inc., consisting of one single-modality imaging center located in Torrance, CA providing MRI and sports medicine services, for cash consideration of $800,000 and the payoff of $81,000 in debt. We have made a fair value determination of the acquired assets and approximately $289,000 of fixed assets, $9,800 of other assets, $100,000 covenant not to compete and $401,000 of goodwill were recorded.   On January 13, 2017, we completed our acquisition of certain assets of Resolution Medical Imaging Corporation for consideration of $4.0 million. The purchase of Resolution was enacted to contribute its assets to a joint venture with Cedars Sinai Medical Corporation which was effective April 1, 2017. See the joint venture formations section within this footnote for further information.   Dispositions   On April 28, 2017 we completed the sale of five imaging centers operating in Rhode Island to Rhode Island Medical Imaging, Inc. for approximately $4.5 million. We recorded a gain of approximately $1.9 million in the second quarter with regard to this transaction and have no remaining imaging centers in the state.   On April 1, 2017 we received from Cedars Sinai Medical Center $5.9 million representing a 25% noncontrolling interest in the West Valley Imaging Group, LLC (“WVI”). The determined net book value of the 25% interest was approximately $3.0 million. The proceeds in excess of the net book value, amounting to $1.8 million net of taxes, were recorded to equity in accordance with accounting guidance. RadNet exercises controlling financial interest and holds a 75% economic interest in WVI.   On April 1, 2017 we completed the sale of 2 wholly owned oncology practices to Cedars Sinai Medical Center in connection with the sale of non-controlling interest of the WVI subsidiary described above for approximately $1.2 million. We recorded a gain of approximately $361,000 on this transaction.   Joint venture formations:   On April 1, 2017 we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA. Total agreed contribution was $2.7 million of cash and assets with RadNet contributing $1.1 million for a 40% economic interest and CSMC contributing $1.6 million for a 60% economic interest. For its contribution, RadNet transferred $80,000 in cash and the net assets acquired in the acquisition of Resolution imaging of $2.5 million. CSMC contributed $120,000 in cash and paid RadNet $1.5 million for the Resolution imaging assets transferred to the venture. RadNet does not have controlling economic interest in SMIG and the investment is accounted for via the equity method.   On January 6, 2017, Image Medical Inc., a wholly owned subsidiary of RadNet, acquired a 49% economic interest ScriptSender, LLC, a partnership held by two individuals which provides secure data transmission services of medical information. Through a management agreement, RadNet provides management and accounting services and receives an agreed upon fee. Image Medical will contribute $3.0 million to the partnership for its 49% ownership stake over a three year period representing the maximum risk in the venture. As of June 30, 2017, the carrying amount of the investment is $2.8 million. We determined that ScriptSender, LLC is a VIE but we are not a primary beneficiary since RadNet does not have the power to direct the activities of the entity that most significantly impact the entity’s economic performance.

Revolving credit facility, notes payable, and capital lease obligations:   As of the six months ended June 30, 2017 our debt obligations consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td colspan="2" style="text-align: center">June 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 64%; padding-left: 10pt; text-indent: -10pt">First Lien Term Loans</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">466,813</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">478,938</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">Second Lien Term Loans</td> <td> </td> <td> </td> <td style="text-align: right">168,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">168,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">Discounts on term loans</td> <td> </td> <td> </td> <td style="text-align: right">(15,915</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(16,783</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019</td> <td> </td> <td> </td> <td style="text-align: right">787</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">980</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">Equipment notes payable at interest rates ranging from 3.3% to 5.6%, due through 2020, collateralized by medical equipment</td> <td> </td> <td> </td> <td style="text-align: right">269</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">341</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Obligations under capital leases at interest rates ranging from 2.5% to 10.8%, due through 2022, collateralized by medical and office equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">9,015</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,256</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt">Total debt obligations</td> <td> </td> <td> </td> <td style="text-align: right">628,969</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">638,732</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Less: current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">(27,317</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(26,557</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Long term portion debt obligations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">601,652</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">612,175</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Term Loans, Revolving Credit Facility and Financing Activity Information:   At June 30, 2017, our credit facilities were comprised of two tranches of term loans (“First Lien Term Loans” and “Second Lien Term Loans”) and a revolving credit facility of $117.5 million (the “Revolving Credit Facility”). As of June 30, 2017, we were in compliance with all covenants under our credit facilities.   Included in our consolidated balance sheets at June 30, 2017 are $618.9 million of senior secured term loan debt (net of unamortized discounts of $15.9 million), broken down by loan agreement as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Face Value</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Discount</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Carrying Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%">First Lien Term Loans</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">466,813</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(14,089</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">452,724</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Second Lien Term Loans</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">168,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(1,826</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">166,174</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">634,813</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">(15,915</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">618,898</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.   The following describes our 2017 financing activities:   Fourth Amendment to First Lien Credit Agreement   On February 2, 2017, we entered into Amendment No. 4 (the “Fourth Amendment”) to our Amended and Restated First Lien Credit and Guaranty Agreement dated July 1, 2016 (as amended from time to time, the “First Lien Credit Agreement”). Pursuant to the Fourth Amendment, the interest rate charged for the applicable margin on the first lien term loans and the revolving credit facility was reduced by 50 basis points, from 3.75% to 3.25%. The minimum LIBOR rate underlying the first lien term loans remains at 1.0%. Except for such reduction in the interest rate on credit extensions, the Fourth Amendment did not result in any other material modifications to First Lien Credit Agreement. RadNet incurred expenses for the transaction in the amount of $543,000, which was recorded to discount on debt and will be amortized over the remaining term of the agreement.   The following describes our prior applicable financing activities:   Restatement Amendment and the First Lien Credit Agreement   On July 1, 2016, (the “Restatement Effective Date”), we entered into Amendment No. 3 to Credit and Guaranty Agreement (the “Restatement Amendment”) pursuant to which we amended and restated our then existing First Lien Credit Agreement. Pursuant to the First Lien Credit Agreement, we have issued $485 million of senior secured term loans (the “First Lien Term Loans”) and established a $117.5 million senior secured revolving credit facility (the “Revolving Credit Facility”). Prior to the Restatement Effective Date, our first lien credit facilities consisted of a Credit and Guaranty Agreement that we entered into on October 10, 2012 (the “Original First Lien Credit Agreement”), as subsequently amended by a first amendment dated April 3, 2013 (the “2013 Amendment”), a second amendment dated March 25, 2014 (the “2014 Amendment”), and a joinder agreement dated April 30, 2015 (the “2015 Joinder” and collectively with the Original First Lien Credit Agreement, the 2013 Amendment and the 2014 Amendment, the “Prior First Lien Credit Agreement”). The First Lien Credit Agreement increased the aggregate principal amount of First Lien Term Loans to $485.0 million and increased the Revolving Credit Facility to $117.5 million. Proceeds from the First Lien Credit Agreement were used to repay the previously outstanding first lien loans under the Prior First Lien Credit Agreement, make a $12.0 million principal payment of the Second Lien Term Loans (as described below), pay costs and expenses related to the First Lien Credit Agreement and provide approximately $10.0 million for general corporate purposes.   Interest. The interest rates payable on the First Lien Term Loans (after giving effect to the Fourth Amendment described above) are (a) the Adjusted Eurodollar Rate (as defined in the First Lien Credit Agreement) plus 3.25% per annum or (b) the Base Rate (as defined in the First Lien Credit Agreement) plus 2.25% per annum. As applied to the First Lien Term Loans, the Adjusted Eurodollar Rate has a minimum floor of 1.0%. The three month Adjusted Eurodollar Rate at June 30, 2017 was 1.30%.    Payments. The scheduled quarterly principal payments of the First Lien Term Loans are approximately $6.1 million, with the balance due at maturity. Prior to the Restatement Amendment, the quarterly principal payments on the first lien term loans under the Prior First Lien Credit Agreement were approximately $6.2 million.   Maturity Date. The maturity date for the First Lien Term Loans shall be on the earliest to occur of (i) July 1, 2023, (ii) the date on which all First Lien Term Loans shall become due and payable in full under the First Lien Credit Agreement, whether by acceleration or otherwise, and (iii) September 25, 2020 if our indebtedness under the Second Lien Credit Agreement has not been repaid, refinanced or extended prior to such date.   Incremental Feature: Under the First Lien Credit Agreement, we can elect to request 1) an increase to the existing Revolving Credit Facility and/or 2) additional First Lien Term Loans, provided that the aggregate amount of such increases or additions does not exceed (A) an amount not in excess of $100.0 million minus any incremental loans requested under the similar provisions of the Second Lien Credit Agreement or (B) if the First Lien Leverage Ratio would not exceed 3.50:1.00 after giving effect to such incremental facilities, an uncapped amount, in each case subject to the conditions and limitations set forth in the First Lien Credit Agreement. Each lender approached to provide all or a portion of any incremental facility may elect or decline, in its sole discretion, to provide any incremental commitment or loan.   Revolving Credit Facility: The First Lien Credit Agreement provides for a $117.5 million Revolving Credit Facility. The termination date of the Revolving Credit Facility is the earliest to occur of: (i) July 1, 2021, (ii) the date the Revolving Credit Facility is permanently reduced to zero pursuant to section 2.13(b) of the First Lien Credit Agreement, which addresses voluntary commitment reductions, (iii) the date of the termination of the Revolving Credit Facility due to specific events of default pursuant to section 8.01 of the First Lien Credit Agreement, and (iv) September 25, 2020 if our indebtedness under the Second Lien Credit Agreement (described below) has not been repaid, refinanced or extended prior to such date. Amounts borrowed under the Revolving Credit Facility bear interest based on types of borrowings as follows (after giving effect to the Fourth Amendment described above): (i) unpaid principal on loans under the Revolving Credit Facility at the Adjusted Eurodollar Rate (as defined in the First Lien Credit Agreement) plus 3.25% per annum or the Base Rate (as defined in the First Lien Credit Agreement) plus 2.25% per annum, (ii) letter of credit fees at 3.25% per annum and fronting fees for letters of credit at 0.25% per annum, in each case on the average aggregate daily maximum amount available to be drawn under all letters of credit issued under the First Lien Credit Agreement, and (iii) commitment fee of 0.5% per annum on the unused revolver balance.   Second Lien Credit Agreement:   On March 25, 2014, we entered into a Second Lien Credit and Guaranty Agreement (as amended from time to time, the “Second Lien Credit Agreement”) pursuant to which we issued $180 million of secured term loans (the “Second Lien Term Loans”). The proceeds from the Second Lien Term Loans were used to redeem our 10 3/8% senior unsecured notes, due 2018, to pay the expenses related to the transaction and for general corporate purposes. On July 1, 2016, in conjunction with the restated First Lien Credit Agreement, a $12.0 million principal payment was made on the Second Lien Term Loans.   The Second Lien Credit Agreement provides for the following:   Interest. The interest rates payable on the Second Lien Term Loans are (a) the Adjusted Eurodollar Rate (as defined in the Second Lien Credit Agreement) plus 7.0% or (b) the Base Rate (as defined in the Second Lien Credit Agreement) plus 6.0%. The Adjusted Eurodollar Rate has a minimum floor of 1.0% on the Second Lien Term Loans. The three month Adjusted Eurodollar Rate at June 30, 2017 was 1.30%. The rate paid on the Second Lien Term Loan at June 30, 2017 was 8.15%.   Payments. There is no scheduled amortization of the principal of the Second Lien Term Loans. Unless otherwise prepaid as a result of the occurrence of certain mandatory prepayment events, all principal will be due and payable on the termination date described below.   Termination. The maturity date for the Second Lien Term Loans is the earlier to occur of (i) March 25, 2021, and (ii) the date on which the Second Lien Term Loans shall otherwise become due and payable in full under the Second Lien Credit Agreement, whether by voluntary prepayment per section 2.13(a) of the Second Lien Credit Agreement or events of default per section 8.01 of the Second Lien Credit Agreement.

Stock Incentive Plans   Options   We have one long-term equity incentive plan which we refer to as the 2006 Equity Incentive Plan, which we first amended and restated as of April 20, 2015 and again on March 9, 2017 (“the Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. As of June 30, 2017, we have reserved for issuance under the 2017 Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the 2017 Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over three to five years and expire five to ten years from the date of grant.   As of June 30, 2017, we had outstanding options to acquire 560,149 shares of our common stock, of which options to acquire 205,000 shares were exercisable. The following summarizes all of our option transactions for the six months ended June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Outstanding Options Under the 2006 Plan</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Shares</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise price Per Common Share</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 48%">Balance, December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">375,626</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 10%; text-align: right">$6.82</td> <td style="width: 2%"> </td> <td style="width: 10%; text-align: center"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">184,523</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">6.30</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">560,149</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">6.65</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center">5.79</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">793,610</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">205,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">7.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center">0.43</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">228,400</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on June 30, 2017 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on June 30, 2017. No options were exercised during the six months ended June 30, 2017. As of June 30, 2017, total unrecognized stock-based compensation expense related to non-vested employee awards was $919,897 which is expected to be recognized over a weighted average period of approximately 3.1 years.   Restricted Stock Awards (“RSA’s”)   The Restated Plan permits the award of restricted stock awards (“RSA’s”). As of June 30, 2017, we have issued a total of 4,945,460 RSA’s of which 470,351 were unvested at June 30, 2017. The following summarizes all unvested RSA’s activities during the six months ended June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted-Average</td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td> </td> <td> </td> <td style="text-align: center">Weighted-Average</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">RSA's</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Term (Years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Fair Value</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%">RSA's unvested at December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">573,145</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 14%; text-align: right">$6.18</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Changes during the period</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 30pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">681,448</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right">$5.98</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 30pt">Vested</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 30pt; text-align: right"> </td> <td style="border-bottom: black 1pt solid; padding-left: 30pt; text-align: right">(784,242</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-left: 30pt"> </td> <td style="padding-left: 30pt"> </td> <td style="padding-left: 30pt; text-align: right"> </td> <td style="padding-left: 30pt"> </td> <td style="padding-left: 30pt"> </td> <td style="padding-left: 30pt; text-align: right">$6.02</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt">RSA's unvested at June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">470,351</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">0.86</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">$6.12</td></tr> </table>   We determine the fair value of all RSA’s based of the closing price of our common stock on award date.    Other stock bonus awards   The Restated Plan also permits the award of stock bonuses not subject to any future service period. These awards are valued and expensed based on the closing price of our common stock on the date of award. During the six months ended June 30, 2017 we issued 10,000 shares relating to these awards, amounting to $59,000 of compensation expense   Plan summary   In sum, of the 14,000,000 shares of common stock reserved for issuance under the Restated Plan, at June 30, 2017, we had issued 13,044,359 total shares between options, RSA’s and other stock awards. With options cancelled and RSA’s forfeited amounting to 2,975,009 and 59,053 shares, respectively, there remain 3,989,703 shares available under the Restated Plan for future issuance.

On July 1, 2017 our wholly owned subsidiary, Advanced Imaging Partners, Inc, sold a 25% noncontrolling interest in one of its imaging centers located in Timonium, Maryland to the University of Maryland St. Joseph Medical Center for $3.9 million.   On August 7, 2017 we acquired Diagnostic Imaging Associates (“DIA”) for $13.0 million in cash and $1.5 million in RadNet common stock. Located in the state of Delaware, DIA operates seven multimodality imaging centers and provides MRI, CT, Ultrasound, Mammography and X-Ray services.

REVENUES -Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. As it relates to BRMG and the NY Groups centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Groups as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Groups. As it relates to non-BRMG and NY Groups centers, namely the affiliated physician groups, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.   Service fee revenues are recorded during the period the services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances are based on historical collection rates of payor reimbursement contract agreements. We also record a provision for doubtful accounts based primarily on historical collection rates related to patient copayments and deductible amounts for patients who have health care coverage under one of our third-party payors.   Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.   Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Six Months Ended</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">June 30,</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">June 30,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%; line-height: 115%">Commercial insurance</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">142,691</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">134,962</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">283,683</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">266,439</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Medicare</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">47,611</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">45,558</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">95,291</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">91,385</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Medicaid</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,525</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,890</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">13,259</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">13,915</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Workers' compensation/personal injury</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,867</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,966</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17,925</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,485</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Other</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">8,362</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">7,383</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">16,648</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">14,377</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Service fee revenue, net of contractual allowances and discounts</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">214,056</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">203,759</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">426,806</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">404,601</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Provision for bad debts</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(11,854</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(12,326</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(23,500</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(22,630</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Net service fee revenue</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">202,202</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">191,433</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">403,306</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">381,971</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Revenue under capitation arrangements</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">27,812</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">27,132</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">55,721</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">52,982</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total net revenue</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">230,014</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">218,565</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">459,027</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">434,953</td> <td style="line-height: 115%"> </td></tr> </table>   (1) Other consists of revenue from teleradiology services, consulting fees and software revenue.

MEANINGFUL USE INCENTIVE - Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software can be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $250,000 and $2.8 million during the six months ended June 30, 2017 and 2016, respectively, relating to this incentive.

DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.8 million and $2.0 million, as of June 30, 2017 and December 31, 2016, respectively and related to the Company’s line of credit. In conjunction with our Fourth Amendment to our First Lien Credit Agreement (as defined below), a net addition of approximately $27,000 was added to deferred financing costs. See Note 5, Revolving Credit Facility, Notes Payable, and Capital Leases for more information.

GOODWILL- Goodwill at June 30, 2017 totaled $244.5 million. Goodwill is recorded as a result of business combinations. Management evaluates goodwill at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. We tested goodwill for impairment on October 1, 2016, noting no impairment, and have not identified any indicators of impairment through June 30, 2017. Activity in goodwill for the six months ended June 30, 2017 is provided below (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 84%; padding-left: 10pt; text-indent: -10pt; line-height: 115%">Balance as of December 31, 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 13%; text-align: right; line-height: 115%">239,553</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill acquired through the acquisition of Resolution Imaging Medical Corp</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,901</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill acquired through the acquisition of MRI Centers of Torrance</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">401</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill disposed through the transfer to Santa Monica Imaging Group JV</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,901</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill acquired through the acquisition of D&D Diagnostics, Inc.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,519</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill acquired through the acquisition of Stockton MRI, Inc.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,101</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Goodwill disposed through the sale of Hematology Oncology</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(110</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Balance as of June 30, 2017</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">244,464</td> <td style="line-height: 115%"> </td></tr> </table>

EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. As of June 30, 2017, we have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 6 Stock-Based Compensation for more information.

COMPREHENSIVE INCOME - ASC 220, Comprehensive Income, establishes rules for reporting and displaying comprehensive income and its components. Our unrealized gains or losses on foreign currency translation adjustments are included in comprehensive income. For the quarter ended December 31, 2016, we entered into an interest rate cap agreement. Assuming perfect effectiveness, any unrealized gains or losses related to the cap agreement that qualify for cash flow hedge accounting are classified as a component of comprehensive income. Any ineffectiveness is recognized in earnings. The components of comprehensive income for the three and six months in the period ended June 30, 2017 are included in the condensed consolidated statements of comprehensive income.

DERIVATIVE INSTRUMENTS - In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued over the life of the 2016 Caps.   At inception, we designated our interest rate cap agreements as cash flow hedges of floating-rate borrowings.  In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e., change in fair value) is initially reported as a component of accumulated other comprehensive income in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As of June 30, 2017, the cash flow hedges were deemed to be effective. No amount is expected to be reclassified into earnings in the next twelve months.   Below represents as of June 30, 2017 the fair value of our 2016 Caps and loss recognized:   The fair value of derivative instruments as of June 30, 2017 is as follows (amounts in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Derivatives</td> <td style="width: 40%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Balance Sheet Location</td> <td style="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Fair Value – Liabilities</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">Interest rate contracts</td> <td style="text-align: center; line-height: 115%">Current and other non-current liabilities</td> <td style="text-align: center; line-height: 115%">$(1,970)</td></tr> </table>    A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss is as follows (amounts in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="line-height: 115%; text-align: center">For the three months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Effective Interest Rate Cap</td> <td style="width: 40%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Amount of Loss Recognized on Derivative</td> <td style="width: 30%; border-bottom: black 1pt solid; text-align: center; line-height: 115%">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">Interest rate contracts</td> <td style="text-align: center; line-height: 115%">($944)</td> <td style="text-align: center; line-height: 115%">Other Comprehensive Loss</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 30%; line-height: 115%"> </td> <td style="width: 40%; line-height: 115%"> </td> <td style="width: 30%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="line-height: 115%; text-align: center">For the six months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Effective Interest Rate Cap</td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Amount of Loss Recognized on Derivative</td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">Interest rate contracts</td> <td style="text-align: center; line-height: 115%">($1,722)</td> <td style="text-align: center; line-height: 115%">Other Comprehensive Loss</td></tr> </table>

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:   Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.   Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.   Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.     The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our consolidated balance sheets, as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">As of June 30, 2017</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Current and other non-current liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Interest Rate Contracts</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(1,970</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(1,970</td> <td style="width: 1%; line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">As of December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Current assets</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Interest Rate Contracts</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">818</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">818</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.   The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="18" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">As of June 30, 2017</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total Fair Value</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total Face Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 35%; line-height: 115%">First Lien Term Loans</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">468,564</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">468,564</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">466,813</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Lien Term Loans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">–</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">169,260</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">–</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">169,260</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">168,000</td> <td style="line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="18" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">As of December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total Face Value</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 35%; line-height: 115%">First Lien Term Loans</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">483,129</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">–</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">483,129</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">478,938</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Lien Term Loans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">–</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">167,580</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">–</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">167,580</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">168,000</td> <td style="line-height: 115%"> </td></tr> </table>   Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.   The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.   We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.

EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Six Months Ended</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center; line-height: 115%">June 30,</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">June 30,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%; padding-left: 10pt; text-indent: -10pt; line-height: 115%">Net income attributable to RadNet, Inc.'s common stockholders</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">5,310</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">3,622</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">4,100</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 9%; text-align: right; line-height: 115%">2,225</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Weighted average number of common shares outstanding during the period</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">46,756,276</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">46,558,944</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">46,662,420</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">46,576,631</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Basic net income per share attributable to RadNet, Inc.'s common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.11</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.08</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.09</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.05</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Weighted average number of common shares outstanding during the period</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,756,276</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,558,944</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,662,420</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46,576,631</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Add nonvested restricted stock subject only to service vesting</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,153</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">77,162</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">198,477</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">155,447</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Add additional shares issuable upon exercise of stock options and warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">189,469</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">246,277</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">207,666</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">228,148</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Weighted average number of common shares used in calculating diluted net income per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">47,195,898</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">46,882,383</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right; line-height: 115%">47,068,563</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">46,960,226</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Diluted net income per share attributable to RadNet, Inc.'s common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.11</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.08</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">0.09</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.05</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">Stock options excluded from the computation of diluted per share amounts:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt; line-height: 115%">Weighted average shares for which the exercise price exceeds average market price of common stock</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">165,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">325,626</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">337,575</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">325,626</td> <td style="line-height: 115%"> </td></tr> </table>

INVESTMENT AT COST - On March 24, 2017, we acquired a 12.5% equity interest in Medic Vision – Imaging Solutions Ltd for $1.0 million. We also have an option to acquire an additional 12.5% equity interest for $1.4 million exercisable within one year from the initial share purchase date. Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. In accordance with ASC 325-20, Cost Method Investments, the investment is recorded at its cost of $1.0 million. No impairment in our investment was noted as of the quarter ended June 30, 2017.

INVESTMENT IN JOINT VENTURES – We have 14 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of June 30, 2017.   Joint venture investment and financial information   The following table is a summary of our investment in joint ventures during the quarter ended June 30, 2017 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 84%; line-height: 115%">Balance as of December 31, 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">43,509</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Equity in earnings in these joint ventures</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,922</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; line-height: 115%">Distribution of earnings</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(3,993</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Equity contributions in existing joint ventures</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">4,062</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Balance as of June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">48,500</td> <td style="line-height: 115%"> </td></tr> </table>     We received management service fees from the centers underlying these joint ventures of approximately $3.5 million and $3.0 million for the quarters ended June 30, 2017 and 2016, respectively and $6.6 million and $5.9 million for the six months ended June 30, 2017 and 2016 respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.   The following table is a summary of key balance sheet data for these joint ventures as of June 30, 2017 and December 31, 2016 and income statement data for the six months ended June 2017 and 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid; line-height: 115%">Balance Sheet Data:</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">June 30, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 66%; line-height: 115%">Current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">41,059</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">40,093</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Noncurrent assets</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">106,421</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">100,146</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="line-height: 115%">Current liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(16,342</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(14,077</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Noncurrent liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(42,680</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(44,405</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; line-height: 115%">Total net assets</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right; line-height: 115%">88,458</td> <td style="line-height: 115%"> </td> <td style="padding-left: 10pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">81,757</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; line-height: 115%">Book value of RadNet joint venture interests</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">42,012</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">38,538</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 115%">Cost in excess of book value of acquired joint venture interests</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 20pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right; line-height: 115%">6,488</td> <td style="line-height: 115%"> </td> <td style="padding-left: 20pt; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">4,970</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 30pt; line-height: 115%">Total value of Radnet joint venture interests</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right; line-height: 115%">48,500</td> <td style="line-height: 115%"> </td> <td style="padding-left: 30pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">43,509</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 30pt; line-height: 115%">Total book value of other joint venture partner interests</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right; line-height: 115%">46,446</td> <td style="line-height: 115%"> </td> <td style="padding-left: 30pt; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">43,219</td> <td style="line-height: 115%"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; line-height: 115%">Income statement data for the six months ended June 30,</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 66%; padding-left: 10pt; line-height: 115%">Net revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">86,981</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">80,917</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Net income</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">10,285</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">13,044</td> <td style="line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">June 30,</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%">Commercial insurance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">142,691</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">134,962</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">283,683</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">266,439</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Medicare</td> <td> </td> <td> </td> <td style="text-align: right">47,611</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">45,558</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">95,291</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">91,385</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Medicaid</td> <td> </td> <td> </td> <td style="text-align: right">6,525</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,890</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,259</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,915</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Workers' compensation/personal injury</td> <td> </td> <td> </td> <td style="text-align: right">8,867</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,966</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17,925</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,485</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">8,362</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">7,383</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">16,648</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">14,377</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Service fee revenue, net of contractual allowances and discounts</td> <td> </td> <td> </td> <td style="text-align: right">214,056</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">203,759</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">426,806</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">404,601</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt">Provision for bad debts</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(11,854</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(12,326</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(23,500</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(22,630</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Net service fee revenue</td> <td> </td> <td> </td> <td style="text-align: right">202,202</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">191,433</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">403,306</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">381,971</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt">Revenue under capitation arrangements</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">27,812</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">27,132</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">55,721</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">52,982</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total net revenue</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">230,014</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">218,565</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">459,027</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">434,953</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 82%; padding-left: 10pt; text-indent: -10pt">Balance as of December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">239,553</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of Resolution Imaging Medical Corp</td> <td> </td> <td> </td> <td style="text-align: right">1,901</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of MRI Centers of Torrance</td> <td> </td> <td> </td> <td style="text-align: right">401</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt">Goodwill disposed through the transfer to Santa Monica Imaging Group JV</td> <td> </td> <td> </td> <td style="text-align: right">(1,901</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of D&D Diagnostics, Inc.</td> <td> </td> <td> </td> <td style="text-align: right">1,519</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of Stockton MRI, Inc.</td> <td> </td> <td> </td> <td style="text-align: right">3,101</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-indent: -10pt">Goodwill disposed through the sale of Hematology Oncology</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(110</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance as of June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">244,464</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 31%; border-bottom: black 1pt solid; text-align: center">Derivatives</td> <td style="width: 38%; border-bottom: black 1pt solid; text-align: center">Balance Sheet Location</td> <td style="width: 31%; border-bottom: black 1pt solid; text-align: center">Fair Value – Liabilities</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">Current and other non-current liabilities</td> <td style="text-align: center">$(1,970)</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">For the three months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="width: 31%; border-bottom: black 1pt solid; text-align: center">Effective Interest Rate Cap</td> <td style="width: 38%; border-bottom: black 1pt solid; text-align: center">Amount of Loss Recognized on Derivative</td> <td style="width: 31%; border-bottom: black 1pt solid; text-align: center">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">($944)</td> <td style="text-align: center">Other Comprehensive Loss</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 31%"> </td> <td style="width: 38%"> </td> <td style="width: 31%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">For the six months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Effective Interest Rate Cap</td> <td style="border-bottom: black 1pt solid; text-align: center">Amount of Loss Recognized on Derivative</td> <td style="border-bottom: black 1pt solid; text-align: center">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">($1,722)</td> <td style="text-align: center">Other Comprehensive Loss</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">As of June 30, 2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 1</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 2</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 3</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Current and other non-current liabilities</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Interest Rate Contracts</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(1,970</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(1,970</td> <td style="width: 1%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">As of December 31, 2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 1</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 2</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 3</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Current assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Interest Rate Contracts</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">818</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">818</td> <td style="width: 1%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: black 1pt solid; text-align: center">As of June 30, 2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 1</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 2</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 3</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Total Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Face Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 30%">First Lien Term Loans</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">468,564</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">468,564</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">466,813</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Second Lien Term Loans</td> <td> </td> <td>$</td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">169,260</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">169,260</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">168,000</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: black 1pt solid; text-align: center">As of December 31, 2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 1</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 2</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Level 3</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Face Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 30%">First Lien Term Loans</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">483,129</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">483,129</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">478,938</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Second Lien Term Loans</td> <td> </td> <td>$</td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">167,580</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">167,580</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">168,000</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center">June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%; padding-left: 10pt; text-indent: -10pt">Net income attributable to RadNet, Inc.'s common stockholders</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">5,310</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">3,622</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">4,100</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,225</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares outstanding during the period</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">46,756,276</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">46,558,944</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">46,662,420</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">46,576,631</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Basic net income per share attributable to RadNet, Inc.'s common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.11</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.08</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.09</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.05</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares outstanding during the period</td> <td> </td> <td> </td> <td style="text-align: right">46,756,276</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,558,944</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,662,420</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,576,631</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt">Add nonvested restricted stock subject only to service vesting</td> <td> </td> <td> </td> <td style="text-align: right">250,153</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">77,162</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">198,477</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">155,447</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Add additional shares issuable upon exercise of stock options and warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">189,469</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">246,277</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">207,666</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">228,148</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares used in calculating diluted net income per share</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">47,195,898</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">46,882,383</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 10pt; text-align: right">47,068,563</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">46,960,226</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Diluted net income per share attributable to RadNet, Inc.'s common stockholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.11</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.08</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">0.09</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.05</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 10pt; text-indent: -10pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-indent: -10pt">Stock options excluded from the computation of diluted per share amounts:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt; text-indent: -10pt">Weighted average shares for which the exercise price exceeds average market price of common stock</td> <td> </td> <td> </td> <td style="text-align: right">165,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">325,626</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">337,575</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">325,626</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid">Balance Sheet Data:</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 64%">Current assets</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">41,059</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">40,093</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Noncurrent assets</td> <td> </td> <td> </td> <td style="text-align: right">106,421</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,146</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Current liabilities</td> <td> </td> <td> </td> <td style="text-align: right">(16,342</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(14,077</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Noncurrent liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(42,680</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(44,405</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total net assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 10pt; text-align: right">88,458</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 10pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">81,757</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-left: 20pt">Book value of RadNet joint venture interests</td> <td> </td> <td>$</td> <td style="text-align: right">42,012</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">38,538</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 20pt">Cost in excess of book value of acquired joint venture interests</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 20pt"> </td> <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">6,488</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-left: 20pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,970</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; padding-left: 30pt">Total value of Radnet joint venture interests</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">48,500</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 30pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,509</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; padding-left: 30pt">Total book value of other joint venture partner interests</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt">$</td> <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">46,446</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 30pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,219</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Income statement data for the six months ended June 30,</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 64%; padding-left: 10pt">Net revenue</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">86,981</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">80,917</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net income</td> <td> </td> <td>$</td> <td style="text-align: right">10,285</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">13,044</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Face Value</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Discount</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Carrying Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 52%">First Lien Term Loans</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">466,813</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(14,089</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">452,724</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Second Lien Term Loans</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">168,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">$</td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(1,826</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">166,174</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">634,813</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">(15,915</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">618,898</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Outstanding Options Under the 2006 Plan</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Shares</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise price Per Common Share</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 48%">Balance, December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">375,626</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 10%; text-align: right">$6.82</td> <td style="width: 2%"> </td> <td style="width: 10%; text-align: center"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">184,523</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">6.30</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">560,149</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">6.65</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center">5.79</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">793,610</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">205,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">7.51</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center">0.43</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">228,400</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

59000000

601652000

612175000

27317000

26557000

628969000

638732000

9015000

7256000

269000

341000

787000

980000

15915000

16783000

81000

1200000

289000

820000

1200000

6600000

5900000

3500000

3000000

46446000 43219000

48500000

43509000

6488000

4970000

42012000

38538000

88458000

81757000

42680000

44405000

16342000

14077000

106421000

100146000

41059000

40093000

2203000

10285000

13044000

86981000 80917000 4062000

198477

155447

250153

77162

-2295000

69000000

66900000

33500000

33000000

69000000

66900000

33500000

33000000

221500000

208000000

108200000

104100000

221500000

208000000

108200000

104100000

47266352

46574904

63649000

52053000

4000

204417000

-146111000

-1394000

6733000

198387000

306000

-150211000

3567000

56916000

48486000

691448

99000

1817000

3158000 3158000

655000

22000

1200000

80000

2800000

1900000

361000

4000000

800000

2400000

4400000

244464000

239553000

1901000

401000

1519000

3101000

110000

4114000

In January 2017, the FASB issued ASU No. 2017-04 (“ASU 2017-04”), Simplifying the Test for Goodwill Impairment. ASU 2017-04 eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the current goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on the current Step 1). ASU 2017-04 is effective for annual and any interim impairment tests for periods beginning after December 15, 2019, with early adoption permitted. We are evaluating the effect of this guidance.   In January 2017, the FASB issued ASU No. 2017-01 (“ASU 2017-01”), Clarifying the Definition of a Business. ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is considered a business. ASU 2017-01 is effective for annual periods beginning after December 31, 2017 including interim periods within those periods. We are evaluating the effect of this guidance.   In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases, (Topic 842): Amendments to the FASB Accounting Standards Codification. ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The amendments in this update are effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2018. Early adoption of the amendments is permitted for all entities. We are currently evaluating the impact this guidance will have on our consolidated financial statements, but expect this adoption will result in a significant increase in the assets and liabilities related to our leased properties and equipment.   In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will become effective for the Company on January 1, 2018. We are continuing to evaluate the effects the adoption of this standard will have on our financial statements and financial disclosures. We believe the most significant impact will be to the presentation of our statement of operations where the provision for bad debts will be recorded as a direct reduction to revenues and will not be presented as a separate line item. We expect to adopt the new standard using the full retrospective application.

1901000

207666

228148

189469

246277

337575

325626

165000

325626

117500000

543000000

During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended.   ADOPTION OF ASU 2016-09 – Compensation – Stock Compensation - In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09 (“ASU 2016-09”), Compensation—Stock Compensation, (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires excess tax benefits and tax deficiencies, which arise due to differences between the measure of compensation expense and the amount deductible for tax purposes, to be recorded directly through the statement of operations when awards vest or are settled. We elected to early adopt the new guidance for the year ended December 31, 2016. Upon adoption using the modified retrospective transition method, we recorded a cumulative effect adjustment to recognize previously unrecognized excess tax benefits which increased deferred tax assets and reduced accumulated deficit by $7.1 million. The current net tax benefit for 2016 resulting from adoption of the new guidance is approximately $400,000 and was reflected in our tax provision at December 31, 2016. The impact on our quarterly financial result for the three months ended June 30, 2016 was additional income tax expense of approximately $3,000. The impact on our financial statements for the six months ended June 30, 2016 is as follows:   CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid">In thousands except per share data</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Provision for income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,073</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(750</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net income attributable to Radnet Inc. common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,225</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted income per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(323</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net decrease in cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Comprehensive income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,256</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less comprehensive income attributable to non-controlling interests</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">–</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Comprehensive income attributable to Radnet Inc. common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,886</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">323</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,209</td> <td style="padding-bottom: 2.5pt; text-align: left">  </td> </tr> </table>   REVENUES -Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payors and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. As it relates to BRMG and the NY Groups centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG and the NY Groups as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG and the NY Groups. As it relates to non-BRMG and NY Groups centers, namely the affiliated physician groups, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.   Service fee revenues are recorded during the period the services are provided based upon the estimated amounts due from the patients and third-party payors. Third-party payors include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances are based on historical collection rates of payor reimbursement contract agreements. We also record a provision for doubtful accounts based primarily on historical collection rates related to patient copayments and deductible amounts for patients who have health care coverage under one of our third-party payors.   Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.   Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left">Commercial insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,691</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">134,962</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">283,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,439</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medicare</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,611</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,558</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,385</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Medicaid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,915</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Workers' compensation/personal injury</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,966</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Other(1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,362</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,383</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,648</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,377</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Service fee revenue, net of contractual allowances and discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">203,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,601</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Provision for bad debts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,854</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,326</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(23,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(22,630</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net service fee revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,202</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">191,433</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403,306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">381,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Revenue under capitation arrangements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,812</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,132</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">55,721</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">52,982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total net revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230,014</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,565</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">459,027</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">434,953</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>  ___________________ (1) Other consists of revenue from teleradiology services, consulting fees and software revenue.   PROVISION FOR BAD DEBTS - We provide for an allowance against accounts receivable that could become uncollectible to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by the historical payment patterns of each type of payor, write-off trends, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us from patients with insurance. Although we attempt to collect deductibles and co-payments due from patients with insurance at the time of service, this attempt to collect at the time of service is not an assessment of the patient’s ability to pay nor are revenues recognized based on an assessment of the patient’s ability to pay. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.   ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.   MEANINGFUL USE INCENTIVE - Under the American Recovery and Reinvestment Act of 2009, a program was enacted that provides financial incentives for providers that successfully implement and utilize electronic health record technology to improve patient care. Our software development team in Canada established an objective to build a Radiology Information System (RIS) software platform that has been awarded Meaningful Use certification. As this certified RIS system is implemented throughout our imaging centers, the radiologists that utilize this software can be eligible for the available financial incentives. In order to receive such incentive payments providers must attest that they have demonstrated meaningful use of the certified RIS in each stage of the program. We account for this meaningful use incentive under the Gain Contingency Model outlined in ASC 450-30. Under this model, we record within non-operating income, meaningful use incentive only after Medicare accepts an attestation from the qualified eligible professional demonstrating meaningful use. We recorded approximately $250,000 and $2.8 million during the six months ended June 30, 2017 and 2016, respectively, relating to this incentive.   DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized on a straight-line basis over the life of the associated loan, which approximates the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.8 million and $2.0 million, as of June 30, 2017 and December 31, 2016, respectively and related to the Company’s line of credit. In conjunction with our Fourth Amendment to our First Lien Credit Agreement (as defined below), a net addition of approximately $27,000 was added to deferred financing costs. See Note 5, Revolving Credit Facility, Notes Payable, and Capital Leases for more information.   INVENTORIES - Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.   PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over the estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 30 years. Maintenance and repairs are charged to expense as incurred.   BUSINESS COMBINATION - Accounting for acquisitions requires us to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.   GOODWILL- Goodwill at June 30, 2017 totaled $244.5 million. Goodwill is recorded as a result of business combinations. Management evaluates goodwill at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. We tested goodwill for impairment on October 1, 2016, noting no impairment, and have not identified any indicators of impairment through June 30, 2017. Activity in goodwill for the six months ended June 30, 2017 is provided below (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 73%; padding-left: 10pt; text-indent: -10pt">Balance as of December 31, 2016</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">239,553</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of Resolution Imaging Medical Corp</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of MRI Centers of Torrance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Goodwill disposed through the transfer to Santa Monica Imaging Group JV</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,901</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of D&D Diagnostics, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,519</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Goodwill acquired through the acquisition of Stockton MRI, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,101</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt; text-indent: -10pt">Goodwill disposed through the sale of Hematology Oncology</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(110</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance as of June 30, 2017</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">244,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.     EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. As of June 30, 2017, we have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 6 Stock-Based Compensation for more information.   COMPREHENSIVE INCOME - ASC 220, Comprehensive Income, establishes rules for reporting and displaying comprehensive income and its components. Our unrealized gains or losses on foreign currency translation adjustments are included in comprehensive income. For the quarter ended December 31, 2016, we entered into an interest rate cap agreement. Assuming perfect effectiveness, any unrealized gains or losses related to the cap agreement that qualify for cash flow hedge accounting are classified as a component of comprehensive income. Any ineffectiveness is recognized in earnings. The components of comprehensive income for the three and six months in the period ended June 30, 2017 are included in the condensed consolidated statements of comprehensive income.    DERIVATIVE INSTRUMENTS - In the fourth quarter of 2016, we entered into two forward interest rate cap agreements ("2016 Caps"). The 2016 Caps will mature in September and October 2020. The 2016 Caps had notional amounts of $150,000,000 and $350,000,000, respectively, which were designated at inception as cash flow hedges of future cash interest payments associated with portions of our variable rate bank debt. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. We are liable for a $5.3 million premium to enter into the caps which is being accrued over the life of the 2016 Caps.   At inception, we designated our interest rate cap agreements as cash flow hedges of floating-rate borrowings.  In accordance with ASC Topic 815, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e., change in fair value) is initially reported as a component of accumulated other comprehensive income in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. As of June 30, 2017, the cash flow hedges were deemed to be effective. No amount is expected to be reclassified into earnings in the next twelve months.   Below represents as of June 30, 2017 the fair value of our 2016 Caps and loss recognized:   The fair value of derivative instruments as of June 30, 2017 is as follows (amounts in thousands):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 31%; text-align: center; border-bottom: Black 1pt solid">Derivatives</td> <td style="width: 37%; text-align: center; border-bottom: Black 1pt solid">Balance Sheet Location</td> <td style="width: 32%; text-align: center; border-bottom: Black 1pt solid">Fair Value – Liabilities</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">Current and other non-current liabilities</td> <td style="text-align: center">$(1,970)</td></tr> </table>    A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss is as follows (amounts in thousands):   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-decoration: underline; text-align: center">For the three months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; width: 31%">Effective Interest Rate Cap</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; width: 37%">Amount of Loss Recognized on Derivative</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; width: 32%">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">($944)</td> <td style="text-align: center">Other Comprehensive Loss</td></tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="width: 31%"> </td> <td style="width: 37%"> </td> <td style="width: 32%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-decoration: underline; text-align: center">For the six months ended June 30, 2017</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Effective Interest Rate Cap</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Amount of Loss Recognized on Derivative</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Location of Loss Recognized in Income on Derivative</td></tr> <tr style="vertical-align: top"> <td>Interest rate contracts</td> <td style="text-align: center">($1,722)</td> <td style="text-align: center">Other Comprehensive Loss</td></tr> </table>   FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:   Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.   Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.   Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.   The table below summarizes the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our consolidated balance sheets, as follows (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">As of June 30, 2017</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Current and other non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 38%; text-align: left; padding-left: 10pt">Interest Rate Contracts</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,970</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,970</td><td style="width: 1%; text-align: left">)</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">As of December 31, 2016</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 38%; text-align: left; padding-left: 10pt">Interest Rate Contracts</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">818</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">818</td><td style="width: 1%; text-align: left"> </td></tr> </table>   The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward LIBOR curve. The forward LIBOR curve is readily available in the public markets or can be derived from information available in the public markets.   The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Face Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 25%; text-align: left">First Lien Term Loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">468,564</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">468,564</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">466,813</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Lien Term Loans</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">169,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">168,000</td><td style="text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Face Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 25%; text-align: left">First Lien Term Loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">483,129</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">483,129</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">478,938</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Lien Term Loans</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">167,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">167,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">168,000</td><td style="text-align: left"> </td></tr> </table>   Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.   The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.   We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.   EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left; padding-left: 10pt; text-indent: -10pt">Net income attributable to RadNet, Inc.'s common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,310</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,622</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares outstanding during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,756,276</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,558,944</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,662,420</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,576,631</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Basic net income per share attributable to RadNet, Inc.'s common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,756,276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,558,944</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,662,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,576,631</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Add nonvested restricted stock subject only to service vesting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,477</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Add additional shares issuable upon exercise of stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">189,469</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">246,277</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">207,666</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">228,148</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares used in calculating diluted net income per share</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,195,898</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,882,383</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,068,563</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,960,226</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Diluted net income per share attributable to RadNet, Inc.'s common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Stock options excluded from the computation of diluted per share amounts:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 20pt; text-indent: -10pt">Weighted average shares for which the exercise price exceeds average market price of common stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">165,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">325,626</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">337,575</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">325,626</td> <td style="text-align: left">  </td> </tr> </table>     INVESTMENT AT COST - On March 24, 2017, we acquired a 12.5% equity interest in Medic Vision – Imaging Solutions Ltd for $1.0 million. We also have an option to acquire an additional 12.5% equity interest for $1.4 million exercisable within one year from the initial share purchase date. Medic Vision, based in Israel, specializes in software packages that provide compliant radiation dose structured reporting and enhanced images from reduced dose CT scans. In accordance with ASC 325-20, Cost Method Investments, the investment is recorded at its cost of $1.0 million. No impairment in our investment was noted as of the quarter ended June 30, 2017.   INVESTMENT IN JOINT VENTURES – We have 14 unconsolidated joint ventures with ownership interests ranging from 35% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.  Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling financial interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of June 30, 2017.   Joint venture investment and financial information   The following table is a summary of our investment in joint ventures during the quarter ended June 30, 2017 (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 73%">Balance as of December 31, 2016</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">43,509</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Equity in earnings in these joint ventures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,922</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Distribution of earnings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,993</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Equity contributions in existing joint ventures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,062</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2016</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   We received management service fees from the centers underlying these joint ventures of approximately $3.5 million and $3.0 million for the quarters ended June 30, 2017 and 2016, respectively and $6.6 million and $5.9 million for the six months ended June 30, 2017 and 2016 respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.   The following table is a summary of key balance sheet data for these joint ventures as of June 30, 2017 and December 31, 2016 and income statement data for the six months ended June 2017 and 2016 (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Balance Sheet Data:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">41,059</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">40,093</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,146</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16,342</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,077</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Noncurrent liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(42,680</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(44,405</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total net assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">88,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">81,757</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 20pt">Book value of RadNet joint venture interests</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">42,012</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,538</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Cost in excess of book value of acquired joint venture interests</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,488</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,970</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total value of Radnet joint venture interests</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,509</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total book value of other joint venture partner interests</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,446</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,219</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>     <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Income statement data for the six months ended June 30,</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left; padding-left: 10pt">Net revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">86,981</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">80,917</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,044</td><td style="text-align: left"> </td></tr> </table>

During the period covered in this report, there have been no material changes to the significant accounting policies we use and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended.   ADOPTION OF ASU 2016-09 – Compensation – Stock Compensation - In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09 (“ASU 2016-09”), Compensation—Stock Compensation, (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires excess tax benefits and tax deficiencies, which arise due to differences between the measure of compensation expense and the amount deductible for tax purposes, to be recorded directly through the statement of operations when awards vest or are settled. We elected to early adopt the new guidance for the year ended December 31, 2016. Upon adoption using the modified retrospective transition method, we recorded a cumulative effect adjustment to recognize previously unrecognized excess tax benefits which increased deferred tax assets and reduced accumulated deficit by $7.1 million. The current net tax benefit for 2016 resulting from adoption of the new guidance is approximately $400,000 and was reflected in our tax provision at December 31, 2016. The impact on our quarterly financial result for the three months ended June 30, 2016 was additional income tax expense of approximately $3,000. The impact on our financial statements for the six months ended June 30, 2016 is as follows:   CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid">In thousands except per share data</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Provision for income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,073</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(750</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net income attributable to Radnet Inc. common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,225</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted income per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(323</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net decrease in cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Comprehensive income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,256</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less comprehensive income attributible to non-controlling interests</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">–</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Comprehensive income attributable to Radnet Inc. common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,886</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">323</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,209</td> <td style="padding-bottom: 2.5pt; text-align: left">  </td> </tr> </table>

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid">In thousands except per share data</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Provision for income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,073</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(750</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,949</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net income attributable to Radnet Inc. common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,225</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted income per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(323</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,295</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net decrease in cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">In thousands</td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impact of adoption</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td><td style="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As currently reported</td><td style="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Comprehensive income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,256</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less comprehensive income attributable to non-controlling interests</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">–</td><td style="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">47</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Comprehensive income attributable to Radnet Inc. common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,886</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">323</td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,209</td> <td style="padding-bottom: 2.5pt; text-align: left">  </td> </tr> </table>

1800000

5627000

4500000

5900000

1200000

Other consists of revenue from teleradiology services, consulting fees and software revenue. EX-101.SCH 7 rdnt-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. RECENT ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 6. STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 7. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 6. STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Derivatives) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Schedule of debt) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Term Loans) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 6. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 6. STOCK-BASED COMPENSATION (Details - RSU's) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 6. STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rdnt-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 rdnt-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 rdnt-20170630_lab.xml XBRL LABEL FILE Equity Components [Axis] Accumulated Deficit Noncontrolling Interest Radnet, Inc.Stockholders' Equity Scenario [Axis] Scenario, Previously Reported [Member] Impact of Adoption [Member] Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Gain (Loss) AwardType [Axis] Restricted Stock [Member] Future Service [Member] Options [Member] Plan Name [Axis] Restated Plan [Member] Derivative Instrument [Axis] Interest Rate Contract [Member] BusinessAcquisition [Axis] ScriptSender LLC [Member] Short-term Debt, Type [Axis] First Lien Term Loans [Member] Second Lien Term Loans [Member] FairValueByFairValueHierarchyLeve [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Securities Financing Transaction [Axis] Total Fair Value [Member] Resolution Imaging Medical Corp [Member] MRI Centers of Torrance [Member] MRI Centers, Inc. [Member] Financial Instrument [Axis] First Lien Term Loan [Member] Total Face Value [Member] Second Lien Term Loans [Member] Property, Plant and Equipment, Type [Axis] Propery and equipment, net [Member] Leasehold Improvements [Member] Credit Derivatives Contract Type [Axis] September 2020 [Member] October 2020 [Member] Medic Vision [Member] Santa Monica Imaging Group JV [Member] D&D Diagnostics, Inc [Member] Stockton MRI, Inc [Member] Hematology Oncology [Member] Disposal Group Classification [Axis] Rhode Island Medical Imaging, Inc [Member] Santa Monica Imaging Group [Member] Long-term Debt, Type [Axis] Fourth Amendment to First Lien [Member] West Valley Imaging Center [Member] Oncology practices [Member] Document and Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Is Entity a Voluntary Filer Is Entity's Reporting Status Current Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable, net Due from affiliates Prepaid expenses and other current assets Assets held for sale Total current assets PROPERTY AND EQUIPMENT, NET OTHER ASSETS Goodwill Other intangible assets Deferred financing costs Investment in joint ventures Deferred tax assets, net of current portion Deposits and other Total assets LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other Due to affiliates Deferred revenue Current portion of deferred rent Current portion of notes payable Current portion of obligations under capital leases Total current liabilities LONG-TERM LIABILITIES Deferred rent, net of current portion Notes payable, net of current portion Obligations under capital lease, net of current portion Other non-current liabilities Total liabilities STOCKHOLDERS' EQUITY Common stock - $.0001 par value, 200,000,000 shares authorized; 47,266,352, and 46,574,904 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively Additional Paid-in-capital Accumulated other comprehensive (loss) gain Accumulated deficit Total RadNet, Inc.'s stockholders' equity Noncontrolling interests Total equity Total liabilities and equity Common stock - par value (in Dollars per share) Common stock - shares authorized Common stock - shares issued Common stock - shares outstanding Income Statement [Abstract] NET REVENUE Service fee revenue, net of contractual allowances and discounts Provision for bad debts Net service fee revenue Revenue under capitation arrangements Total net revenue OPERATING EXPENSES Cost of operations, excluding depreciation and amortization Depreciation and amortization Loss on sale and disposal of equipment Severance costs Total operating expenses INCOME FROM OPERATIONS OTHER INCOME AND EXPENSES Interest expense Meaningful use incentive Equity in earnings of joint ventures Gain on sale of imaging centers Gain on return of common stock Other expenses Total other expenses INCOME BEFORE INCOME TAXES Provision for income taxes NET INCOME Net income (loss) attributable to noncontrolling interests NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS WEIGHTED AVERAGE SHARES OUTSTANDING - Basic WEIGHTED AVERAGE SHARES OUTSTANDING - Diluted Statement of Comprehensive Income [Abstract] NET INCOME Foreign currency translation adjustments Change in fair value of cash flow hedge, net of taxes COMPREHENSIVE INCOME Less comprehensive income (loss) attributable to non-controlling interests COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Issuance of common stock upon exercise of options/warrants, shares Issuance of common stock upon exercise of options/warrants Stock-based compensation Issuance of restricted stock and other awards, shares Issuance of restricted stock and other awards, value Sale to noncontrolling interests, net of taxes Contributions from noncontrolling interests Return of common stock, shares Return of common stock, value Distributions paid to noncontrolling interest Change in cumulative foreign currency translation adjustment Net income Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net income to net cash provided by operating activities: Provision for bad debts Distributions from joint ventures Amortization of deferred financing costs and loan discount Stock-based compensation Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Accounts receivable Other current assets Other assets Deferred taxes Deferred rent Deferred revenue Accounts payable, accrued expenses and other Net cash provided by operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities Investment at cost Purchase of property and equipment Proceeds from sale of equipment Proceeds from sale of imaging facilities Cash contribution from partner in JV formation EX-101.PRE 11 rdnt-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 04, 2017
Document and Entity Information
Entity Registrant Name	RadNet, Inc.
Entity Central Index Key	0000790526
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		47,266,352
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 12,707	$ 20,638
Accounts receivable, net	170,155	164,210
Due from affiliates	3,087	2,428
Prepaid expenses and other current assets	21,702	28,435
Assets held for sale	0	2,203
Total current assets	207,651	217,914
PROPERTY AND EQUIPMENT, NET	253,179	247,725
OTHER ASSETS
Goodwill	244,464	239,553
Other intangible assets	41,506	42,682
Deferred financing costs	1,806	2,004
Investment in joint ventures	48,500	43,509
Deferred tax assets, net of current portion	48,416	50,356
Deposits and other	6,298	5,733
Total assets	851,820	849,476
CURRENT LIABILITIES
Accounts payable, accrued expenses and other	107,452	111,166
Due to affiliates	12,079	13,141
Deferred revenue	1,961	1,516
Current portion of deferred rent	2,991	2,961
Current portion of notes payable	21,933	22,031
Current portion of obligations under capital leases	5,384	4,526
Total current liabilities	151,800	155,341
LONG-TERM LIABILITIES
Deferred rent, net of current portion	26,429	24,799
Notes payable, net of current portion	598,020	609,445
Obligations under capital lease, net of current portion	3,632	2,730
Other non-current liabilities	8,290	5,108
Total liabilities	788,171	797,423
STOCKHOLDERS' EQUITY
Common stock - $.0001 par value, 200,000,000 shares authorized; 47,266,352, and 46,574,904 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	4	4
Additional Paid-in-capital	204,417	198,387
Accumulated other comprehensive (loss) gain	(1,394)	306
Accumulated deficit	(146,111)	(150,211)
Total RadNet, Inc.'s stockholders' equity	56,916	48,486
Noncontrolling interests	6,733	3,567
Total equity	63,649	52,053
Total liabilities and equity	$ 851,820	$ 849,476

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock - par value (in Dollars per share)	$ 0.0001	$ .0001
Common stock - shares authorized	200,000,000	200,000,000
Common stock - shares issued	47,266,352	46,574,904
Common stock - shares outstanding	47,266,352	46,574,904

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
NET REVENUE
Service fee revenue, net of contractual allowances and discounts	$ 214,056	$ 203,759	$ 426,806	$ 404,601
Provision for bad debts	(11,854)	(12,326)	(23,500)	(22,630)
Net service fee revenue	202,202	191,433	403,306	381,971
Revenue under capitation arrangements	27,812	27,132	55,721	52,982
Total net revenue	230,014	218,565	459,027	434,953
OPERATING EXPENSES
Cost of operations, excluding depreciation and amortization	198,611	194,062	404,065	390,888
Depreciation and amortization	16,612	15,811	33,266	32,223
Loss on sale and disposal of equipment	453	441	408	441
Severance costs	177	173	380	340
Total operating expenses	215,853	210,487	438,119	423,892
INCOME FROM OPERATIONS	14,161	8,078	20,908	11,061
OTHER INCOME AND EXPENSES
Interest expense	10,303	10,745	20,543	21,426
Meaningful use incentive	0	0	(250)	(2,808)
Equity in earnings of joint ventures	(2,994)	(3,274)	(4,922)	(5,553)
Gain on sale of imaging centers	(2,301)	0	(2,301)	0
Gain on return of common stock	0	(5,032)	0	(5,032)
Other expenses	7	4	10	6
Total other expenses	5,015	2,443	13,080	8,039
INCOME BEFORE INCOME TAXES	9,146	5,635	7,828	3,022
Provision for income taxes	(3,523)	(2,256)	(3,065)	(750)
NET INCOME	5,623	3,379	4,763	2,272
Net income (loss) attributable to noncontrolling interests	313	(243)	663	47
NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 5,310	$ 3,622	$ 4,100	$ 2,225
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 0.11	$ 0.08	$ 0.09	$ 0.05
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 0.11	$ 0.08	$ 0.09	$ 0.05
WEIGHTED AVERAGE SHARES OUTSTANDING - Basic	46,756,276	46,558,944	46,662,420	46,576,631
WEIGHTED AVERAGE SHARES OUTSTANDING - Diluted	47,195,898	46,882,383	47,068,563	46,960,226

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 5,623	$ 3,379	$ 4,763	$ 2,272
Foreign currency translation adjustments	20	(20)	22	(16)
Change in fair value of cash flow hedge, net of taxes	(944)	0	(1,722)
COMPREHENSIVE INCOME	4,699	3,359	3,063	2,256
Less comprehensive income (loss) attributable to non-controlling interests	313	(243)	663	47
COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 4,386	$ 3,602	$ 2,400	$ 2,209

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Radnet, Inc.Stockholders' Equity	Noncontrolling Interest	Total
Beginning balance, shares at Dec. 31, 2016	46,574,904
Beginning balance, value at Dec. 31, 2016	$ 4	$ 198,387	$ 306	$ (150,211)	$ 48,486	$ 3,567	$ 52,053
Stock-based compensation		4,114			4,114		4,114
Issuance of restricted stock and other awards, shares	691,448
Issuance of restricted stock and other awards, value		99			99		99
Sale to noncontrolling interests, net of taxes		1,817			1,817		1,817
Contributions from noncontrolling interests						3,158	3,158
Distributions paid to noncontrolling interest						(655)	(655)
Change in cumulative foreign currency translation adjustment			22		22		22
Change in fair value of cash flow hedge, net of taxes			(1,722)		(1,722)		(1,722)
Net income				4,100	4,100	663	4,763
Ending balance, shares at Jun. 30, 2017	47,266,352
Ending balance, value at Jun. 30, 2017	$ 4	$ 204,417	$ (1,394)	$ (146,111)	$ 56,916	$ 6,733	$ 63,649

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 4,763	$ 2,272
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	33,266	32,223
Provision for bad debts	23,500	22,630
Gain on return of common stock	0	(5,032)
Equity in earnings of joint ventures	(4,922)	(5,553)
Distributions from joint ventures	3,993	2,098
Amortization of deferred financing costs and loan discount	1,636	2,738
Loss on sale and disposal of equipment	408	441
Gain on sale of imaging centers	(2,301)	0
Stock-based compensation	4,314	3,761
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable	(29,445)	(24,873)
Other current assets	4,553	8,454
Other assets	(835)	220
Deferred taxes	1,940	10
Deferred rent	1,830	1,052
Deferred revenue	445	0
Accounts payable, accrued expenses and other	7,014	10,983
Net cash provided by operating activities	50,159	51,424
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities	(9,904)	(6,603)
Investment at cost	(500)	0
Purchase of property and equipment	(42,647)	(40,267)
Proceeds from sale of equipment	63	63
Proceeds from sale of imaging facilities	5,627	0
Cash contribution from partner in JV formation	1,473	994
Equity contributions in existing and purchase of interest in joint ventures	(80)	(734)
Net cash used in investing activities	(45,968)	(46,547)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable	(3,769)	(6,310)
Payments on Term Loan Debt/Senior Notes	(12,125)	(12,357)
Deferred financing costs and debt discount	(570)	0
Distributions paid to noncontrolling interests	(655)	(157)
Proceeds from the sale of non-controlling interests, net of taxes	4,850	0
Contributions from noncontrolling partners	125	0
Proceeds on revolving credit facility	139,400	235,500
Payments on revolving credit facility	(139,400)	(221,700)
Proceeds from issuance of common stock upon exercise of options	0	150
Net cash used in financing activities	(12,144)	(4,874)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	22	(16)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(7,931)	(13)
CASH AND CASH EQUIVALENTS, beginning of period	20,638	446
CASH AND CASH EQUIVALENTS, end of period	12,707	433
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest	19,023	18,545
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Purchase of equipment and leasehold improvements not yet paid for	17,500	15,400
Capital lease debt related to radiology equipment	5,200	1,300
Investment in joint venture	3,000	0
Transfer of fixed assets to new joint venture	$ 2,500	$ 0

XML 19 R8.htm IDEA: XBRL DOCUMENT

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF BUSINESS AND BASIS OF PRESENTATION

XML 20 R9.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

In thousands except per share data	As previously reported			Impact of adoption		As currently reported
Provision for income taxes	$	(1,073	)	$	323	$	(750	)
Net income		1,949			323		2,272
Net income attributable to Radnet Inc. common shareholders		1,902			323		2,225
Basic and diluted income per share		0.04			0.01		0.05

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands	As previously reported			Impact of adoption			As currently reported
Net income	$	1,949		$	323		$	2,272
Deferred taxes		333			(323	)		10
Others		(2,295	)		–			(2,295	)
Net decrease in cash and cash equivalents	$	(13	)	$	–		$	(13	)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

In thousands	As previously reported			Impact of adoption		As currently reported
Net income	$	1,949		$	323	$	2,272
Foreign currency translation adjustments		(16	)		–		(16	)
Comprehensive income		1,933			323		2,256
Less comprehensive income attributable to non-controlling interests		47			–		47
Comprehensive income attributable to Radnet Inc. common shareholders	$	1,886		$	323	$	2,209

Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Commercial insurance	$	142,691		$	134,962		$	283,683		$	266,439
Medicare		47,611			45,558			95,291			91,385
Medicaid		6,525			6,890			13,259			13,915
Workers' compensation/personal injury		8,867			8,966			17,925			18,485
Other⁽¹⁾		8,362			7,383			16,648			14,377
Service fee revenue, net of contractual allowances and discounts		214,056			203,759			426,806			404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue	$	230,014		$	218,565		$	459,027		$	434,953

___________________

⁽¹⁾ Other consists of revenue from teleradiology services, consulting fees and software revenue.

INVENTORIES - Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.

Balance as of December 31, 2016		239,553
Goodwill acquired through the acquisition of Resolution Imaging Medical Corp		1,901
Goodwill acquired through the acquisition of MRI Centers of Torrance		401
Goodwill disposed through the transfer to Santa Monica Imaging Group JV		(1,901	)
Goodwill acquired through the acquisition of D&D Diagnostics, Inc.		1,519
Goodwill acquired through the acquisition of Stockton MRI, Inc.		3,101
Goodwill disposed through the sale of Hematology Oncology		(110	)
Balance as of June 30, 2017	$	244,464

Below represents as of June 30, 2017 the fair value of our 2016 Caps and loss recognized:

The fair value of derivative instruments as of June 30, 2017 is as follows (amounts in thousands):

Derivatives	Balance Sheet Location	Fair Value – Liabilities
Interest rate contracts	Current and other non-current liabilities	$(1,970)

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss is as follows (amounts in thousands):

For the three months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($944)	Other Comprehensive Loss


For the six months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($1,722)	Other Comprehensive Loss

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

	As of June 30, 2017
	Level 1		Level 2			Level 3		Total
Current and other non-current liabilities
Interest Rate Contracts	$	–	$	(1,970	)	$	–	$	(1,970	)

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total
Current assets
Interest Rate Contracts	$	–	$	818	$	–	$	818

The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):

	As of June 30, 2017
	Level 1		Level 2		Level 3		Total Fair Value		Total Face Value
First Lien Term Loans	$	–	$	468,564	$	–	$	468,564	$	466,813
Second Lien Term Loans	$	–	$	169,260	$	–		169,260	$	168,000

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total		Total Face Value
First Lien Term Loans	$	–	$	483,129	$	–	$	483,129	$	478,938
Second Lien Term Loans	$	–	$	167,580	$	–	$	167,580	$	168,000

Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.

The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Net income attributable to RadNet, Inc.'s common stockholders	$	5,310	$	3,622	$	4,100	$	2,225

BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Basic net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Add nonvested restricted stock subject only to service vesting		250,153		77,162		198,477		155,447
Add additional shares issuable upon exercise of stock options and warrants		189,469		246,277		207,666		228,148
Weighted average number of common shares used in calculating diluted net income per share		47,195,898		46,882,383		47,068,563		46,960,226
Diluted net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock		165,000		325,626		337,575		325,626

Joint venture investment and financial information

The following table is a summary of our investment in joint ventures during the quarter ended June 30, 2017 (in thousands):

Balance as of December 31, 2016	$	43,509
Equity in earnings in these joint ventures		4,922
Distribution of earnings		(3,993	)
Equity contributions in existing joint ventures		4,062
Balance as of June 30, 2016	$	48,500

Balance Sheet Data:	June 30, 2017			December 31, 2016
Current assets	$	41,059		$	40,093
Noncurrent assets		106,421			100,146
Current liabilities		(16,342	)		(14,077	)
Noncurrent liabilities		(42,680	)		(44,405	)
Total net assets	$	88,458		$	81,757

Book value of RadNet joint venture interests	$	42,012		$	38,538
Cost in excess of book value of acquired joint venture interests		6,488			4,970
Total value of Radnet joint venture interests	$	48,500		$	43,509

Total book value of other joint venture partner interests	$	46,446		$	43,219

Income statement data for the six months ended June 30,	2017		2016
Net revenue	$	86,981	$	80,917
Net income	$	10,285	$	13,044

XML 21 R10.htm IDEA: XBRL DOCUMENT

3. RECENT ACCOUNTING STANDARDS

6 Months Ended

Jun. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

RECENT ACCOUNTING STANDARDS

XML 22 R11.htm IDEA: XBRL DOCUMENT

4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE

Acquisitions

Dispositions

Joint venture formations:

XML 23 R12.htm IDEA: XBRL DOCUMENT

5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES

Revolving credit facility, notes payable, and capital lease obligations:

As of the six months ended June 30, 2017 our debt obligations consist of the following (in thousands):

	June 30,			December 31,
	2017			2016

First Lien Term Loans		466,813			478,938

Second Lien Term Loans		168,000			168,000

Discounts on term loans		(15,915	)		(16,783	)

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019		787			980

Equipment notes payable at interest rates ranging from 3.3% to 5.6%, due through 2020, collateralized by medical equipment		269			341

Obligations under capital leases at interest rates ranging from 2.5% to 10.8%, due through 2022, collateralized by medical and office equipment		9,015			7,256
Total debt obligations		628,969			638,732
Less: current portion		(27,317	)		(26,557	)
Long term portion debt obligations	$	601,652		$	612,175

Term Loans, Revolving Credit Facility and Financing Activity Information:

	Face Value		Discount			Total Carrying Value
First Lien Term Loans	$	466,813	$	(14,089	)	$	452,724
Second Lien Term Loans	$	168,000	$	(1,826	)	$	166,174
Total	$	634,813	$	(15,915	)	$	618,898

Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.

The following describes our 2017 financing activities:

Fourth Amendment to First Lien Credit Agreement

The following describes our prior applicable financing activities:

Restatement Amendment and the First Lien Credit Agreement

Second Lien Credit Agreement:

The Second Lien Credit Agreement provides for the following:

XML 24 R13.htm IDEA: XBRL DOCUMENT

6. STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Stock Incentive Plans

Options

Outstanding Options Under the 2006 Plan	Shares		Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value

Balance, December 31, 2016		375,626	$6.82
Granted		184,523	6.30
Balance, June 30, 2017		560,149	6.65	5.79	$	793,610
Exercisable at June 30, 2017		205,000	7.51	0.43		228,400

Restricted Stock Awards (“RSA’s”)

				Weighted-Average
				Remaining
				Contractual		Weighted-Average
	RSA's			Term (Years)		Fair Value
RSA's unvested at December 31, 2016		573,145				$6.18
Changes during the period
Granted		681,448				$5.98
Vested		(784,242	)			$6.02
RSA's unvested at June 30, 2017		470,351			0.86	$6.12

We determine the fair value of all RSA’s based of the closing price of our common stock on award date.

Other stock bonus awards

Plan summary

XML 25 R14.htm IDEA: XBRL DOCUMENT

7. SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

XML 26 R15.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

RESTATEMENT DUE TO ADOPTION OF ACCOUNTING PRONOUNCEMENT

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

In thousands except per share data	As previously reported			Impact of adoption		As currently reported
Provision for income taxes	$	(1,073	)	$	323	$	(750	)
Net income		1,949			323		2,272
Net income attributable to Radnet Inc. common shareholders		1,902			323		2,225
Basic and diluted income per share		0.04			0.01		0.05

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands	As previously reported			Impact of adoption			As currently reported
Net income	$	1,949		$	323		$	2,272
Deferred taxes		333			(323	)		10
Others		(2,295	)		–			(2,295	)
Net decrease in cash and cash equivalents	$	(13	)	$	–		$	(13	)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

In thousands	As previously reported			Impact of adoption		As currently reported
Net income	$	1,949		$	323	$	2,272
Foreign currency translation adjustments		(16	)		–		(16	)
Comprehensive income		1,933			323		2,256
Less comprehensive income attributible to non-controlling interests		47			–		47
Comprehensive income attributable to Radnet Inc. common shareholders	$	1,886		$	323	$	2,209

REVENUES

Our service fee revenue, net of contractual allowances and discounts, the provision for bad debts, and revenue under capitation arrangements are summarized in the following table (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Commercial insurance	$	142,691		$	134,962		$	283,683		$	266,439
Medicare		47,611			45,558			95,291			91,385
Medicaid		6,525			6,890			13,259			13,915
Workers' compensation/personal injury		8,867			8,966			17,925			18,485
Other		8,362			7,383			16,648			14,377
Service fee revenue, net of contractual allowances and discounts		214,056			203,759			426,806			404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue	$	230,014		$	218,565		$	459,027		$	434,953

⁽¹⁾ Other consists of revenue from teleradiology services, consulting fees and software revenue.

PROVISION FOR BAD DEBTS

ACCOUNTS RECEIVABLE

MEANINGFUL USE INCENTIVE

DEFERRED FINANCING COSTS

INVENTORIES

INVENTORIES - Inventories, consisting mainly of medical supplies, are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method.

PROPERTY AND EQUIPMENT

BUSINESS COMBINATION

GOODWILL

Balance as of December 31, 2016		239,553
Goodwill acquired through the acquisition of Resolution Imaging Medical Corp		1,901
Goodwill acquired through the acquisition of MRI Centers of Torrance		401
Goodwill disposed through the transfer to Santa Monica Imaging Group JV		(1,901	)
Goodwill acquired through the acquisition of D&D Diagnostics, Inc.		1,519
Goodwill acquired through the acquisition of Stockton MRI, Inc.		3,101
Goodwill disposed through the sale of Hematology Oncology		(110	)
Balance as of June 30, 2017	$	244,464

INCOME TAXES

EQUITY BASED COMPENSATION

COMPREHENSIVE INCOME

DERIVATIVE INSTRUMENTS

Below represents as of June 30, 2017 the fair value of our 2016 Caps and loss recognized:

The fair value of derivative instruments as of June 30, 2017 is as follows (amounts in thousands):

Derivatives	Balance Sheet Location	Fair Value – Liabilities
Interest rate contracts	Current and other non-current liabilities	$(1,970)

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive loss is as follows (amounts in thousands):

For the three months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($944)	Other Comprehensive Loss


For the six months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($1,722)	Other Comprehensive Loss

FAIR VALUE MEASUREMENTS

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

	As of June 30, 2017
	Level 1		Level 2			Level 3		Total
Current and other non-current liabilities
Interest Rate Contracts	$	–	$	(1,970	)	$	–	$	(1,970	)

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total
Current assets
Interest Rate Contracts	$	–	$	818	$	–	$	818

The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):

	As of June 30, 2017
	Level 1		Level 2		Level 3		Total Fair Value		Total Face Value
First Lien Term Loans	$	–	$	468,564	$	–	$	468,564	$	466,813
Second Lien Term Loans	$	–	$	169,260	$	–		169,260	$	168,000

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total		Total Face Value
First Lien Term Loans	$	–	$	483,129	$	–	$	483,129	$	478,938
Second Lien Term Loans	$	–	$	167,580	$	–	$	167,580	$	168,000

Our revolving credit facility had no aggregate principal amount outstanding as of June 30, 2017.

The estimated fair value of our long-term debt, which is discussed in Note 5, was determined using Level 2 inputs primarily related to comparable market prices.

EARNINGS PER SHARE

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Net income attributable to RadNet, Inc.'s common stockholders	$	5,310	$	3,622	$	4,100	$	2,225

BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Basic net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Add nonvested restricted stock subject only to service vesting		250,153		77,162		198,477		155,447
Add additional shares issuable upon exercise of stock options and warrants		189,469		246,277		207,666		228,148
Weighted average number of common shares used in calculating diluted net income per share		47,195,898		46,882,383		47,068,563		46,960,226
Diluted net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock		165,000		325,626		337,575		325,626

INVESTMENT AT COST

INVESTMENT IN JOINT VENTURES

Joint venture investment and financial information

The following table is a summary of our investment in joint ventures during the quarter ended June 30, 2017 (in thousands):

Balance as of December 31, 2016	$	43,509
Equity in earnings in these joint ventures		4,922
Distribution of earnings		(3,993	)
Equity contributions in existing joint ventures		4,062
Balance as of June 30, 2016	$	48,500

Balance Sheet Data:	June 30, 2017			December 31, 2016
Current assets	$	41,059		$	40,093
Noncurrent assets		106,421			100,146
Current liabilities		(16,342	)		(14,077	)
Noncurrent liabilities		(42,680	)		(44,405	)
Total net assets	$	88,458		$	81,757

Book value of RadNet joint venture interests	$	42,012		$	38,538
Cost in excess of book value of acquired joint venture interests		6,488			4,970
Total value of Radnet joint venture interests	$	48,500		$	43,509

Total book value of other joint venture partner interests	$	46,446		$	43,219

Income statement data for the six months ended June 30,	2017		2016
Net revenue	$	86,981	$	80,917
Net income	$	10,285	$	13,044

XML 27 R16.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Impact of recent accounting standards change

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

In thousands except per share data	As previously reported			Impact of adoption		As currently reported
Provision for income taxes	$	(1,073	)	$	323	$	(750	)
Net income		1,949			323		2,272
Net income attributable to Radnet Inc. common shareholders		1,902			323		2,225
Basic and diluted income per share		0.04			0.01		0.05

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands	As previously reported			Impact of adoption			As currently reported
Net income	$	1,949		$	323		$	2,272
Deferred taxes		333			(323	)		10
Others		(2,295	)		–			(2,295	)
Net decrease in cash and cash equivalents	$	(13	)	$	–		$	(13	)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

In thousands	As previously reported			Impact of adoption		As currently reported
Net income	$	1,949		$	323	$	2,272
Foreign currency translation adjustments		(16	)		–		(16	)
Comprehensive income		1,933			323		2,256
Less comprehensive income attributable to non-controlling interests		47			–		47
Comprehensive income attributable to Radnet Inc. common shareholders	$	1,886		$	323	$	2,209

Service Fee Revenue

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Commercial insurance	$	142,691		$	134,962		$	283,683		$	266,439
Medicare		47,611			45,558			95,291			91,385
Medicaid		6,525			6,890			13,259			13,915
Workers' compensation/personal injury		8,867			8,966			17,925			18,485
Other		8,362			7,383			16,648			14,377
Service fee revenue, net of contractual allowances and discounts		214,056			203,759			426,806			404,601
Provision for bad debts		(11,854	)		(12,326	)		(23,500	)		(22,630	)
Net service fee revenue		202,202			191,433			403,306			381,971
Revenue under capitation arrangements		27,812			27,132			55,721			52,982
Total net revenue	$	230,014		$	218,565		$	459,027		$	434,953

Schedule of goodwill and other intangible assets

Balance as of December 31, 2016		239,553
Goodwill acquired through the acquisition of Resolution Imaging Medical Corp		1,901
Goodwill acquired through the acquisition of MRI Centers of Torrance		401
Goodwill disposed through the transfer to Santa Monica Imaging Group JV		(1,901	)
Goodwill acquired through the acquisition of D&D Diagnostics, Inc.		1,519
Goodwill acquired through the acquisition of Stockton MRI, Inc.		3,101
Goodwill disposed through the sale of Hematology Oncology		(110	)
Balance as of June 30, 2017	$	244,464

Fair value of derivatives

Derivatives	Balance Sheet Location	Fair Value – Liabilities
Interest rate contracts	Current and other non-current liabilities	$(1,970)

Effect of derivative instruments on comprehensive income

For the three months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($944)	Other Comprehensive Loss


For the six months ended June 30, 2017
Effective Interest Rate Cap	Amount of Loss Recognized on Derivative	Location of Loss Recognized in Income on Derivative
Interest rate contracts	($1,722)	Other Comprehensive Loss

Schedule of fair value of assets and liabilities

	As of June 30, 2017
	Level 1		Level 2			Level 3		Total
Current and other non-current liabilities
Interest Rate Contracts	$	–	$	(1,970	)	$	–	$	(1,970	)

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total
Current assets
Interest Rate Contracts	$	–	$	818	$	–	$	818

	As of June 30, 2017
	Level 1		Level 2		Level 3		Total Fair Value		Total Face Value
First Lien Term Loans	$	–	$	468,564	$	–	$	468,564	$	466,813
Second Lien Term Loans	$	–	$	169,260	$	–		169,260	$	168,000

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total		Total Face Value
First Lien Term Loans	$	–	$	483,129	$	–	$	483,129	$	478,938
Second Lien Term Loans	$	–	$	167,580	$	–	$	167,580	$	168,000

Earnings per share

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Net income attributable to RadNet, Inc.'s common stockholders	$	5,310	$	3,622	$	4,100	$	2,225

BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Basic net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period		46,756,276		46,558,944		46,662,420		46,576,631
Add nonvested restricted stock subject only to service vesting		250,153		77,162		198,477		155,447
Add additional shares issuable upon exercise of stock options and warrants		189,469		246,277		207,666		228,148
Weighted average number of common shares used in calculating diluted net income per share		47,195,898		46,882,383		47,068,563		46,960,226
Diluted net income per share attributable to RadNet, Inc.'s common stockholders	$	0.11	$	0.08	$	0.09	$	0.05

Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock		165,000		325,626		337,575		325,626

Investment in joint ventures

Balance as of December 31, 2016	$	43,509
Equity in earnings in these joint ventures		4,922
Distribution of earnings		(3,993	)
Equity contributions in existing joint ventures		4,062
Balance as of June 30, 2016	$	48,500

Joint venture investment and financial information

Balance Sheet Data:	June 30, 2017			December 31, 2016
Current assets	$	41,059		$	40,093
Noncurrent assets		106,421			100,146
Current liabilities		(16,342	)		(14,077	)
Noncurrent liabilities		(42,680	)		(44,405	)
Total net assets	$	88,458		$	81,757

Book value of RadNet joint venture interests	$	42,012		$	38,538
Cost in excess of book value of acquired joint venture interests		6,488			4,970
Total value of Radnet joint venture interests	$	48,500		$	43,509

Total book value of other joint venture partner interests	$	46,446		$	43,219

Income statement data for the six months ended June 30,	2017		2016
Net revenue	$	86,981	$	80,917
Net income	$	10,285	$	13,044

XML 28 R17.htm IDEA: XBRL DOCUMENT

5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Schedule of notes payable, line of credit and capital lease obligations

	June 30,			December 31,
	2017			2016

First Lien Term Loans		466,813			478,938

Second Lien Term Loans		168,000			168,000

Discounts on term loans		(15,915	)		(16,783	)

Promissory note payable to the former owner of a practice acquired at an interest rate of 1.5% due through 2019		787			980

Equipment notes payable at interest rates ranging from 3.3% to 5.6%, due through 2020, collateralized by medical equipment		269			341

Obligations under capital leases at interest rates ranging from 2.5% to 10.8%, due through 2022, collateralized by medical and office equipment		9,015			7,256
Total debt obligations		628,969			638,732
Less: current portion		(27,317	)		(26,557	)
Long term portion debt obligations	$	601,652		$	612,175

Term loans and financing activity

	Face Value		Discount			Total Carrying Value
First Lien Term Loans	$	466,813	$	(14,089	)	$	452,724
Second Lien Term Loans	$	168,000	$	(1,826	)	$	166,174
Total	$	634,813	$	(15,915	)	$	618,898

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

6. STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock option activity

Outstanding Options Under the 2006 Plan	Shares		Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value

Balance, December 31, 2016		375,626	$6.82
Granted		184,523	6.30
Balance, June 30, 2017		560,149	6.65	5.79	$	793,610
Exercisable at June 30, 2017		205,000	7.51	0.43		228,400

Restricted Stock Awards activity

				Weighted-Average
				Remaining
				Contractual		Weighted-Average
	RSA's			Term (Years)		Fair Value
RSA's unvested at December 31, 2016		573,145				$6.18
Changes during the period
Granted		681,448				$5.98
Vested		(784,242	)			$6.02
RSA's unvested at June 30, 2017		470,351			0.86	$6.12

XML 30 R19.htm IDEA: XBRL DOCUMENT

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BRMG and NY Groupls revenues	$ 33,500	$ 33,000	$ 69,000	$ 66,900
BRMG and NY Groups operating expenses	33,500	33,000	69,000	66,900
Total billed net service fee revenue	108,200	104,100	221,500	208,000
Management services provided to BRMG and NY Groups	108,200	$ 104,100	221,500	$ 208,000
BRMG and NY Groups accounts receivable	104,000		104,000		$ 100,000
BRMG and NY Groups accounts payable	$ 11,200		$ 11,200		$ 9,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Provision for income taxes	$ (3,523)	$ (2,256)	$ (3,065)	$ (750)
Net income	5,623	3,379	4,763	2,272
Net loss attributable to Radnet Inc. common shareholders	$ 5,310	$ 3,622	$ 4,100	$ 2,225
Basic and diluted loss per share				$ 0.05
Scenario, Previously Reported [Member]
Provision for income taxes				$ (1,073)
Net income				1,949
Net loss attributable to Radnet Inc. common shareholders				$ 1,902
Basic and diluted loss per share				$ 0.04
Impact of Adoption [Member]
Provision for income taxes				$ 323
Net income				323
Net loss attributable to Radnet Inc. common shareholders				$ 323
Basic and diluted loss per share				$ 0.01

XML 32 R21.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income	$ 5,623	$ 3,379	$ 4,763	$ 2,272
Deferred taxes			1,940	10
Others				(2,295)
Net decrease in cash and cash equivalents			$ (7,931)	(13)
Scenario, Previously Reported [Member]
Net income				1,949
Deferred taxes				333
Others				(2,295)
Net decrease in cash and cash equivalents				(13)
Impact of Adoption [Member]
Net income				323
Deferred taxes				(323)
Others				0
Net decrease in cash and cash equivalents				$ 0

XML 33 R22.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income	$ 5,623	$ 3,379	$ 4,763	$ 2,272
Foreign currency translation adjustments	20	(20)	22	(16)
Comprehensive income	4,699	3,359	3,063	2,256
Less comprehensive income attributible to non-controlling interests	313	(243)	663	47
Comprehensive income attributable to Radnet Inc. common shareholders	$ 4,386	$ 3,602	$ 2,400	2,209
Scenario, Previously Reported [Member]
Net income				1,949
Foreign currency translation adjustments				(16)
Comprehensive income				1,933
Less comprehensive income attributible to non-controlling interests				47
Comprehensive income attributable to Radnet Inc. common shareholders				1,886
Impact of Adoption [Member]
Net income				323
Foreign currency translation adjustments				0
Comprehensive income				323
Less comprehensive income attributible to non-controlling interests				0
Comprehensive income attributable to Radnet Inc. common shareholders				$ 323

XML 34 R23.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Commercial Insurance

$ 142,691

$ 134,962

$ 283,683

$ 266,439

Medicare

47,611

45,558

95,291

91,385

Medicaid

6,525

6,890

13,259

13,915

Workers Compensation/Personal Injury

8,867

8,966

17,925

18,485

Other

^[1]

8,362

7,383

16,648

14,377

Service fee revenue, net of contractual allowances and discounts

214,056

203,759

426,806

404,601

Provision for bad debts

(11,854)

(12,326)

(23,500)

(22,630)

Net service fee revenue

202,202

191,433

403,306

381,971

Revenue under capitation arrangements

27,812

27,132

55,721

52,982

Total net revenue

$ 230,014

$ 218,565

$ 459,027

$ 434,953

[1]	Other consists of revenue from teleradiology services, consulting fees and software revenue.

XML 35 R24.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Goodwill, beginning balance	$ 239,553
Goodwill, ending balance	244,464
Resolution Imaging Medical Corp [Member]
Goodwill acquired through acquisitions	1,901
MRI Centers of Torrance [Member]
Goodwill acquired through acquisitions	401
Santa Monica Imaging Group JV [Member]
Goodwill disposed through the transfer	(1,901)
D&D Diagnostics, Inc [Member]
Goodwill acquired through acquisitions	1,519
Stockton MRI, Inc [Member]
Goodwill acquired through acquisitions	3,101
Hematology Oncology [Member]
Goodwill disposed through sale	$ (110)

XML 36 R25.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Derivatives) $ in Thousands	Jun. 30, 2017 USD ($)
Interest Rate Contract [Member]
Derivative asset fair value	$ (1,970)

XML 37 R26.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017
Amount of loss recognized on derivative	$ (944)	$ 0	$ (1,722)
Interest Rate Contract [Member]
Amount of loss recognized on derivative	$ (944)		$ (1,722)

XML 38 R27.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Level 1 [Member]
Interest rate contracts	$ 0	$ 0
Level 1 [Member] \| First Lien Term Loan [Member]
Term Loans	0	0
Level 1 [Member] \| Second Lien Term Loans [Member]
Term Loans	0	0
Level 2 [Member]
Interest rate contracts	(1,970)	818
Level 2 [Member] \| First Lien Term Loans [Member]
Term Loans	468,564	483,129
Level 2 [Member] \| Second Lien Term Loans [Member]
Term Loans	169,260	167,580
Level 3 [Member]
Interest rate contracts	0	0
Level 3 [Member] \| First Lien Term Loans [Member]
Term Loans	0	0
Level 3 [Member] \| Second Lien Term Loans [Member]
Term Loans	0	0
Total Fair Value [Member]
Interest rate contracts	(1,970)	818
Total Fair Value [Member] \| First Lien Term Loans [Member]
Term Loans	468,564	483,129
Total Fair Value [Member] \| Second Lien Term Loans [Member]
Term Loans	169,260	167,580
Total Face Value [Member] \| First Lien Term Loans [Member]
Term Loans	466,813	478,938
Total Face Value [Member] \| Second Lien Term Loans [Member]
Term Loans	$ 168,000	$ 168,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net income attributable to Radnet, Inc. common stockholders	$ 5,310	$ 3,622	$ 4,100	$ 2,225
BASIC NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Weighted average shares outstanding - Basic	46,756,276	46,558,944	46,662,420	46,576,631
Basic net income per share attributable to Radnet, Inc. common stockholders	$ 0.11	$ 0.08	$ 0.09	$ 0.05
DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS
Weighted average shares outstanding during the period - Basic	46,756,276	46,558,944	46,662,420	46,576,631
Add nonvested restricted stock subject only to service vesting	250,153	77,162	198,477	155,447
Add additional shares issuable upon exercise of stock options and warrants	189,469	246,277	207,666	228,148
Weighted average shares outstanding - Diluted	47,195,898	46,882,383	47,068,563	46,960,226
Diluted net income per share attributable to RadNet, Inc.'s common stockholders	$ 0.11	$ 0.08	$ 0.09	$ 0.05
Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock	165,000	325,626	337,575	325,626

XML 40 R29.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Beginning balance			$ 43,509
Equity in earnings in these joint ventures	$ 2,994	$ 3,274	4,922	$ 5,553
Distribution of earnings			(3,993)	$ (2,098)
Equity contributions in existing joint ventures			4,062
Ending balance	$ 48,500		$ 48,500

XML 41 R30.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Key financial data for joint ventures
Current assets	$ 41,059		$ 40,093
Noncurrent assets	106,421		100,146
Current liabilities	(16,342)		(14,077)
Noncurrent liabilities	(42,680)		(44,405)
Total net assets	88,458		81,757
Book value of Radnet joint venture interests	42,012		38,538
Cost in excess of book value of acquired joint venture interests	6,488		4,970
Total value of Radnet joint venture interests	48,500		43,509
Total book value of other joint venture partner interests	46,446		$ 43,219
Net revenue	86,981	$ 80,917
Net income	$ 10,285	$ 13,044

XML 42 R31.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF ACCOUNTING POLICIES (Details Narrative) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($) Integer shares	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Integer shares	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Meaningful use incentive income	$ 0	$ 0	$ 250	$ 2,808
Deferred financing costs, net of accumulated amortization	1,800		1,800		$ 2,000
Increase in deferred financing costs			27
Goodwill	244,464		244,464		$ 239,553
Premium liability for 2016 Caps	$ 5,300		$ 5,300
Number of unconsolidated joint ventures \| Integer	14		14
Ownership percentage ranges			35% to 55%
Management service fees	$ 3,500	$ 3,000	$ 6,600	$ 5,900
Propery and equipment, net [Member]
Property and equipment useful lives			3 to 15 years
Leasehold Improvements [Member]
Property and equipment useful lives			3 to 30 years
Restated Plan [Member]
Common stock reserved for issuance \| shares	14,000,000		14,000,000
October 2020 [Member]
Notional amounts	$ 350,000		$ 350,000
September 2020 [Member]
Notional amounts	150,000		150,000
Medic Vision [Member]
Investment recorded at cost	$ 1,000		1,000
Impairment of investment			$ 0
Ownership interest			12.50%

XML 43 R32.htm IDEA: XBRL DOCUMENT

4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Proceeds from sale of business	$ 5,627,000	$ 0
Transfer of fixed assets to new joint venture	2,500,000	$ 0
Rhode Island Medical Imaging, Inc [Member]
Proceeds from sale of business	4,500,000
Gain on sale of investment	1,900,000
Oncology practices [Member]
Proceeds from sale of business	1,200,000
Gain on sale of investment	361,000
Stockton MRI, Inc [Member]
Consideration transferred	4,400,000
Fixed assets acquired	1,200,000
Goodwill acquired	3,100,000
Intangible assets acquired	50,000
D&D Diagnostics, Inc [Member]
Consideration transferred	2,400,000
Payments to acquire business	1,200,000
Payoff of debt	1,200,000
Fixed assets acquired	820,000
Other assets acquired	16,000
Goodwill acquired	1,500,000
MRI Centers, Inc. [Member]
Consideration transferred	800,000
Payoff of debt	81,000
Fixed assets acquired	289,000
Other assets acquired	9,800
Goodwill acquired	401,000
Intangible assets acquired	100,000
Resolution Imaging Medical Corp [Member]
Consideration transferred	4,000,000
West Valley Imaging Center [Member]
Proceeds from sale of business	5,900,000
Proceeds in excess of book value	1,800,000
Santa Monica Imaging Group [Member]
Payments to acquire business	80,000
Transfer of fixed assets to new joint venture	$ 2,500,000
Equity Method Investment, Ownership Percentage	40.00%
ScriptSender LLC [Member]
Transfer of fixed assets to new joint venture	$ 3,000,000
Equity Method Investment, Ownership Percentage	49.00%
Carrying amount of investment	$ 2,800,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Schedule of debt) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Discounts on term loan and notes	$ (15,915)	$ (16,783)
Promissory notes payable	787	980
Equipment notes payable	269	341
Obligations under capital leases	9,015	7,256
Total notes payable, line of credit and capital lease obligations	628,969	638,732
Less: current portion	(27,317)	(26,557)
Total notes payable, line of credit and capital lease obligations, long-term	601,652	612,175
First Lien Term Loans [Member]
Term loans	466,813	478,938
Second Lien Term Loans [Member]
Term loans	$ 168,000	$ 168,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Term Loans) $ in Thousands	Jun. 30, 2017 USD ($)
Term loans face value	$ 634,813
Term loans discount	(15,915)
Term loan carrying value	618,898
First Lien Term Loans [Member]
Term loans face value	466,813
Term loans discount	(14,089)
Term loan carrying value	452,724
Second Lien Term Loans [Member]
Term loans face value	168,000
Term loans discount	(1,826)
Term loan carrying value	$ 166,174

XML 46 R35.htm IDEA: XBRL DOCUMENT

5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details Narrative) $ in Thousands	Jun. 30, 2017 USD ($)
Total credit facilities outstanding	$ 117,500
Fourth Amendment to First Lien [Member]
Discount on debt	$ 543,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 47 R36.htm IDEA: XBRL DOCUMENT

6. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) - Options [Member]	6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares
STOCK BASED COMPENSATION
Begining Balance \| shares	375,626
Granted \| shares	184,523
Ending Balance \| shares	560,149
Exercisable at the end \| shares	205,000
Weighted Average Exercise price Per Common Share
Begining Balance \| $ / shares	$ 6.82
Granted \| $ / shares	6.30
Ending Balance \| $ / shares	6.65
Exercisable at the end \| $ / shares	$ 7.51
Weighted Average Remaining Contractual Life
Ending Balance	5 years 9 months 14 days
Exercisable at the end	5 months 5 days
Aggregate Intrinsic Value
Aggregate value outstanding \| $	$ 793,610
Aggregate value exercisable \| $	$ 228,400

XML 48 R37.htm IDEA: XBRL DOCUMENT

6. STOCK-BASED COMPENSATION (Details - RSU's) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
RSA's outstanding, beginning balance \| shares	573,145
RSA's granted \| shares	681,448
RSA's vested \| shares	(784,242)
RSA's outstanding, ending balance \| shares	470,351
Weighted-Average Remaining Contractual Term	10 months 10 days
Weighted-average fair value, beginning balance \| $ / shares	$ 6.18
Weighted-average fair value, granted \| $ / shares	5.98
Weighted-average fair value, vested \| $ / shares	6.02
Weighted-average fair value, ending balance \| $ / shares	$ 6.12

XML 49 R38.htm IDEA: XBRL DOCUMENT

6. STOCK-BASED COMPENSATION (Details Narrative) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($) shares
Unrecognized stock-based compensation expense \| $	$ 919,897
Unrecognized expense weighted average period	3 years 1 month 6 days
Restated Plan [Member]
Shares authorized	14,000,000
Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards	3,989,703
Awards issued to date	13,044,359
Options cancelled	2,975,009
RSA's forfeited	59,053
Options [Member]
Options exercised	0
Options granted	184,523
Future Service [Member]
Options granted	10,000
Compensation expense \| $	$ 59,000
Restricted Stock [Member]
Awards issued to date	4,945,460
RSA's unvested	470,351

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 97 262 1 true 41 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://radnet.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://radnet.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://radnet.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://radnet.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://radnet.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentation 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES Sheet http://radnet.com/role/SignificantAccountingPolicies 2. SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - 3. RECENT ACCOUNTING STANDARDS Sheet http://radnet.com/role/RecentAccountingStandards 3. RECENT ACCOUNTING STANDARDS Notes 10 false false R11.htm 00000011 - Disclosure - 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE Sheet http://radnet.com/role/FacilityAcquisitionsAndAssetsHeldForSale 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE Notes 11 false false R12.htm 00000012 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES Notes http://radnet.com/role/NotesPayableLineOfCreditAndCapitalLeases 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES Notes 12 false false R13.htm 00000013 - Disclosure - 6. STOCK-BASED COMPENSATION Sheet http://radnet.com/role/Stock-basedCompensation 6. STOCK-BASED COMPENSATION Notes 13 false false R14.htm 00000014 - Disclosure - 7. SUBSEQUENT EVENTS Sheet http://radnet.com/role/SubsequentEvents 7. SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://radnet.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://radnet.com/role/SummaryOfSignificantAccountingPoliciesTables 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables 16 false false R17.htm 00000017 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Tables) Notes http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesTables 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Tables) Tables http://radnet.com/role/NotesPayableLineOfCreditAndCapitalLeases 17 false false R18.htm 00000018 - Disclosure - 6. STOCK-BASED COMPENSATION (Tables) Sheet http://radnet.com/role/Stock-basedCompensationTables 6. STOCK-BASED COMPENSATION (Tables) Tables http://radnet.com/role/Stock-basedCompensation 18 false false R19.htm 00000019 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://radnet.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://radnet.com/role/NatureOfBusinessAndBasisOfPresentation 19 false false R20.htm 00000020 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS) Sheet http://radnet.com/role/RecentAccountingStandardsDetails 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS) Details http://radnet.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-CondensedConsolidatedStatementsOfCashFlows 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS) Details http://radnet.com/role/SignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-CondensedConsolidatedStatementsOfComprehensiveLoss 2. SIGNIFICANT ACCOUNTING POLICIES (Details - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS) Details http://radnet.com/role/SignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-Revenue 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Revenue) Details http://radnet.com/role/SignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-Goodwill 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Goodwill) Details http://radnet.com/role/SignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Derivatives) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-FairValueDerivatives 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Value Derivatives) Details http://radnet.com/role/SignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) Sheet http://radnet.com/role/SignificantAccountingPoliciesDetails-GainOnDerivative 2. SIGNIFICANT ACCOUNTING POLICIES (Details - Gain on Derivative) Details http://radnet.com/role/SignificantAccountingPolicies 26 false false R27.htm 00000027 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) Sheet http://radnet.com/role/FairValueMeasurementsDetails 2. SUMMARY OF ACCOUNTING POLICIES (Details - Fair Value Measurements) Details 27 false false R28.htm 00000028 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) Sheet http://radnet.com/role/EarningsPerShareDetails 2. SUMMARY OF ACCOUNTING POLICIES (Details - Earnings Per Share) Details 28 false false R29.htm 00000029 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Sheet http://radnet.com/role/SummaryOfAccountingPoliciesDetails-InvestmentInJointVentures 2. SUMMARY OF ACCOUNTING POLICIES (Details - Investment in Joint Ventures) Details 29 false false R30.htm 00000030 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Sheet http://radnet.com/role/SummaryOfAccountingPoliciesDetails-KeyFinancialDataOnJointVentures 2. SUMMARY OF ACCOUNTING POLICIES (Details - Key Financial Data on Joint Ventures) Details 30 false false R31.htm 00000031 - Disclosure - 2. SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Sheet http://radnet.com/role/SummaryOfAccountingPoliciesDetailsNarrative 2. SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Details 31 false false R32.htm 00000032 - Disclosure - 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE (Details Narrative) Sheet http://radnet.com/role/FacilityAcquisitionsAndAssetsHeldForSaleDetailsNarrative 4. FACILITY ACQUISITIONS AND ASSETS HELD FOR SALE (Details Narrative) Details http://radnet.com/role/FacilityAcquisitionsAndAssetsHeldForSale 32 false false R33.htm 00000033 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Schedule of debt) Notes http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesDetails-ScheduleOfDebt 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Schedule of debt) Details http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesTables 33 false false R34.htm 00000034 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Term Loans) Notes http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesDetails-TermLoans 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details - Term Loans) Details http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesTables 34 false false R35.htm 00000035 - Disclosure - 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details Narrative) Notes http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesDetailsNarrative 5. REVOLVING CREDIT FACILITY, NOTES PAYABLE AND CAPITAL LEASES (Details Narrative) Details http://radnet.com/role/RevolvingCreditFacilityNotesPayableAndCapitalLeasesTables 35 false false R36.htm 00000036 - Disclosure - 6. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Sheet http://radnet.com/role/Stock-basedCompensationDetails-outstandingOptionsAndWarrants 6. STOCK-BASED COMPENSATION (Details-Outstanding options and warrants) Details http://radnet.com/role/Stock-basedCompensationTables 36 false false R37.htm 00000037 - Disclosure - 6. STOCK-BASED COMPENSATION (Details - RSU's) Sheet http://radnet.com/role/Stock-basedCompensationDetails-Rsus 6. STOCK-BASED COMPENSATION (Details - RSU's) Details http://radnet.com/role/Stock-basedCompensationTables 37 false false R38.htm 00000038 - Disclosure - 6. STOCK-BASED COMPENSATION (Details Narrative) Sheet http://radnet.com/role/Stock-basedCompensationDetailsNarrative 6. STOCK-BASED COMPENSATION (Details Narrative) Details http://radnet.com/role/Stock-basedCompensationTables 38 false false All Reports Book All Reports rdnt-20170630.xml rdnt-20170630.xsd rdnt-20170630_cal.xml rdnt-20170630_def.xml rdnt-20170630_lab.xml rdnt-20170630_pre.xml true true ZIP 56 0001683168-17-002009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-17-002009-xbrl.zip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�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
R23%,PDZ8B\Y [)'4GN6$VIJ)X_ M*A2#%3-<6<'4BK,*[T=G_]A'?5S#T4:UA1__)\[[:1#V2L\(^JP;3J*]1$&' MM;):>3H2S+>>P; 7W>B;',K?J9:XVV\K:B>O"[4&)?'%(JI*.';8^TZ3[7[J MG:J;2T<*.J\;79Q9#9J9;CW!S7;J.UB,@+4""[C2VEGCYE68-[+3='405:=& MTKW0VCE:S.7+[*@8J^^#WQNH2J>3M:BL2["8\[6+;;_5M'$_;WT?MQ_[@XZB=7;M%5E9E]KV-@TE2UFBR-2=QNPM MDTG8VLQ-U>O>K>+>KV]S,O1=;NB[TV\I[3K%>B5]5L+7@UT;_=2=.#O=@G.) MO&UBT#DCQJL!Z3,3/M7QUVM7O_R!_^09X\S_._%=P./_?O8]W^$C[CP;$WY# MWJX/(#4-\?NOHXL/;,HGQEPWW7]^.&E_^*_NL$7_+]YV-KA6=X-MQ]&;BETB M4C"?N7>/B7CXF\#T6FJOJZ6@2:Z;]YV]$U4[::OOO%/5U'XW\SOQL_-@,,.V MV]3Z;;6?>F-BU9POS+1'K=?M9GYALG%9>]!O;^;L(O:V88&MR3%LJ>ECL>$% M.\"1"75]K=O;!HX0O]0Z\DLPFW'K([N!,9.+;PM )BRT.VIN $8SV_'PH4^V MX]@OP$3;\O69MC\QG_X-.SSO34NU.YP MY6B\^ZY"@,N$*;77'[1W ^Z3[QH6=UU0^V/#HM-U#@?, 'N-_GAP@.<>.3^PG"\E_A=-EC$<#1<>9ZW*P7H/1W0#^-7QLF*1HX#O@G.D7QUYP MQUMB0R=46/'XV\WG:&N*@RGP'B:*WTA=L;'!(5S3/MH 3"SR- MY>/OBCQ>^,W9]-EP;6=YHUOZ$Z=/K.G9=&Y8!LAV .>9?^8K)NH;B8A^9Z-%>=39LO0]G:GF_ M4;_@3[;]G;*4[AY)"?[+-BSO&_S>=_@7W?$L[EP%(X2W-W\[O4Y'W$*V>W'Q M8&[=-9S!( M[2/WJTN!/1L1AOU6%;#OP/OPH)8!Q%T R>: &'3;6>B<$9"HR]PYV+1;8V
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end